<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64400</article-id><article-id pub-id-type="doi">10.7554/eLife.64400</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>A critical residue in the α<sub>1</sub>M2–M3 linker regulating mammalian GABA<sub>A</sub> receptor pore gating by diazepam</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-213620"><name><surname>Nors</surname><given-names>Joseph W</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213621"><name><surname>Gupta</surname><given-names>Shipra</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-114412"><name><surname>Goldschen-Ohm</surname><given-names>Marcel P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1466-9808</contrib-id><email>marcel.goldschen-ohm@austin.utexas.edu</email><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>University of Texas at Austin, Department of Neuroscience</institution><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Islas</surname><given-names>Leon D</given-names></name><role>Reviewing Editor</role><aff><institution>Universidad Nacional Autónoma de México</institution><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Senior Editor</role><aff><institution>National Institute of Neurological Disorders and Stroke, National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>16</day><month>02</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64400</elocation-id><history><date date-type="received" iso-8601-date="2020-10-27"><day>27</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-02-15"><day>15</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Nors et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Nors et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64400-v2.pdf"/><abstract><p>Benzodiazepines (BZDs) are a class of widely prescribed psychotropic drugs that modulate activity of GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs), neurotransmitter-gated ion channels critical for synaptic transmission. However, the physical basis of this modulation is poorly understood. We explore the role of an important gating domain, the α<sub>1</sub>M2–M3 linker, in linkage between the BZD site and pore gate. To probe energetics of this coupling without complication from bound agonist, we use a gain of function mutant (α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub>) directly activated by BZDs. We identify a specific residue whose mutation (α<sub>1</sub>V279A) more than doubles the energetic contribution of the BZD positive modulator diazepam (DZ) to pore opening and also enhances DZ potentiation of GABA-evoked currents in a wild-type background. In contrast, other linker mutations have little effect on DZ efficiency, but generally impair unliganded pore opening. Our observations reveal an important residue regulating BZD-pore linkage, thereby shedding new light on the molecular mechanism of these drugs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>benzodiazepine</kwd><kwd>diazepam</kwd><kwd>GABAA receptor</kwd><kwd>M2-M3 linker</kwd><kwd>allosteric modulator</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>Xenopus</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008562</institution-id><institution>University of Texas at Austin</institution></institution-wrap></funding-source><award-id>Department of Neuroscience Startup</award-id><principal-award-recipient><name><surname>Goldschen-Ohm</surname><given-names>Marcel P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008562</institution-id><institution>University of Texas at Austin</institution></institution-wrap></funding-source><award-id>STARS</award-id><principal-award-recipient><name><surname>Goldschen-Ohm</surname><given-names>Marcel P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The role of an important gating domain in linkage between the benzodiazepine drug-binding site and the pore gate in GABA<sub>A</sub> receptors.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Benzodiazepines (BZDs) (e.g. Valium, Xanax) are one of the most widely prescribed psychotropic drugs today. An estimated nearly 100 million adults in the United States are prescribed a BZD annually (<xref ref-type="bibr" rid="bib1">Agarwal and Landon, 2019</xref>; <xref ref-type="bibr" rid="bib3">Bachhuber et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Olfson et al., 2015</xref>). Their anxiolytic and sedative properties are used as therapies for conditions including anxiety, panic, insomnia, seizures, muscle spasms, pain, and alcohol withdrawal (<xref ref-type="bibr" rid="bib44">Möhler et al., 2002</xref>). Although largely effective, BZDs have undesirable effects, including tolerance, addiction, dependence, and withdrawal symptoms, and are often co-abused with alcohol and opioids (<xref ref-type="bibr" rid="bib15">Fluyau et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Schmitz, 2016</xref>; <xref ref-type="bibr" rid="bib30">Jones and McAninch, 2015</xref>; <xref ref-type="bibr" rid="bib29">Jones et al., 2010</xref>). Novel therapies with reduced risks are imperative for safer long-term treatment options.</p><p>The therapeutic effects of BZDs are conferred upon binding to and modulating the activity of GABA<sub>A</sub>Rs, which are the primary inhibitory neurotransmitter-gated ion channels in the central nervous system (<xref ref-type="bibr" rid="bib68">Smart and Stephenson, 2019</xref>). GABA<sub>A</sub>Rs are part of the Cys-loop superfamily of pentameric ligand-gated ion channels (pLGICs) including homologous glycine (Gly), nicotinic acetylcholine (nACh), serotonin type 3 (5-HT<sub>3</sub>), and zinc-activated receptors as well as prokaryotic homologs (<xref ref-type="bibr" rid="bib54">Pless and Sivilotti, 2018</xref>; <xref ref-type="bibr" rid="bib46">Nemecz et al., 2016</xref>; <xref ref-type="bibr" rid="bib71">Tasneem et al., 2004</xref>; <xref ref-type="bibr" rid="bib11">Connolly and Wafford, 2004</xref>). Each pentameric GABA<sub>A</sub>R is comprised of subtype-specific combinations of five homologous but nonidentical subunits (α<sub>1-6</sub>, β<sub>1-3</sub>, γ<sub>1-3</sub>, δ, ε, π, θ, ρ<sub>1-3</sub>) that together form a central chloride conducting pore (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib50">Olsen and Sieghart, 2008</xref>). The most prominent subtype at synapses is comprised of α<sub>1</sub>, β<sub>n</sub>, and γ<sub>2</sub> subunits (<xref ref-type="bibr" rid="bib64">Sieghart and Sperk, 2002</xref>). GABA<sub>A</sub>Rs provide a critical balance with excitatory signaling for normal neural function, and not surprisingly, their dysfunction is related to disorders such as epilepsy, autism spectrum disorder, intellectual disability, schizophrenia, and neurodevelopmental disorders such as fragile X syndrome (<xref ref-type="bibr" rid="bib26">Hernandez and Macdonald, 2019</xref>; <xref ref-type="bibr" rid="bib16">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Mahdavi et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Braat and Kooy, 2015</xref>; <xref ref-type="bibr" rid="bib74">Vien et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Rudolph and Möhler, 2014</xref>; <xref ref-type="bibr" rid="bib38">Limon et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Ramamoorthi and Lin, 2011</xref>; <xref ref-type="bibr" rid="bib69">Solís-Añez et al., 2007</xref>). Although pharmacological manipulation of GABA<sub>A</sub>Rs is a powerful approach to tuning neural signaling, the rational design of novel therapies is challenged by a lack of understanding of the molecular mechanism by which drugs such as BZDs modulate channel behavior.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Visual representation of an α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub> GABA<sub>A</sub> receptor from cryo-EM map PDB 6X3X.</title><p>(<bold>A,B</bold>) View from the extracellular space (<bold>A</bold>) and parallel to the membrane plane (<bold>B</bold>). Bound GABA and DZ are shown as gold and lavender spheres, respectively. The 9' pore residue from each subunit is shown in stick representation, all leucine except for the mutation α<sub>1</sub>L9'T, which was generated in PyMol as a visualization aid. One of the two α<sub>1</sub>M2–M3 linkers is shown as cyan spheres in (<bold>B</bold>). (<bold>C</bold>) Same view as in (<bold>A</bold>) for a slice through the transmembrane domains indicated by the solid box in (<bold>B</bold>). (<bold>D</bold>) Detail for the dashed box in (<bold>B</bold>). The α<sub>1</sub>M2–M3 linker (L276-T283; rat numbering) is colored cyan with side chains shown in stick representation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Sequence alignment of M2–M3 linker regions for subunits from several members of the pLGIC superfamily.</title><p>Position of M2 and M3 helices are indicated above the sequences. The pore gate L9' residue and mutated M2–M3 linker residues are shown in bold.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig1-figsupp1-v2.tif"/></fig></fig-group><p>In conjunction with structural models of mostly homomeric pLGICs, recent cryo-EM models of heteromeric GABA<sub>A</sub>Rs with bound neurotransmitter and BZD provide an important conceptual aid to understand the mechanism of action of these drugs (<xref ref-type="bibr" rid="bib33">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Masiulis et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Laverty et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Phulera et al., 2018</xref>; <xref ref-type="bibr" rid="bib78">Zhu et al., 2018</xref>). Consistent with earlier functional studies (<xref ref-type="bibr" rid="bib66">Sigel and Ernst, 2018</xref>; <xref ref-type="bibr" rid="bib67">Sigel and Lüscher, 2011</xref>; <xref ref-type="bibr" rid="bib65">Sigel, 2002</xref>; <xref ref-type="bibr" rid="bib75">Wagner and Czajkowski, 2001</xref>; <xref ref-type="bibr" rid="bib34">Kucken et al., 2000</xref>; <xref ref-type="bibr" rid="bib42">McKernan et al., 1998</xref>; <xref ref-type="bibr" rid="bib55">Pritchett et al., 1989</xref>; <xref ref-type="bibr" rid="bib18">Gibbs et al., 1985</xref>), they show that BZDs are bound at a specific recognition site in the extracellular domain between α and γ subunits (<xref ref-type="fig" rid="fig1">Figure 1</xref>). However, these structures have yet to clarify the mechanism by which BZDs modulate channel activity.</p><p>Kinetic models of interacting domains and thermodynamic linkage analysis can be used to estimate the energy of interaction between binding sites and the pore gate from bulk measures of ensemble average activity (<xref ref-type="bibr" rid="bib21">Goldschen-Ohm et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Chowdhury and Chanda, 2013</xref>; <xref ref-type="bibr" rid="bib77">Wyman and Gill, 1990</xref>). Coupled with mutagenesis or other perturbations, these interactions can be probed to elucidate their physical basis. However, these approaches are challenged for BZDs because they do not evoke robust channel opening by themselves, but instead modulate responses to an agonist such as GABA. Thus, typical experimental measures reflect channels with both agonist and BZD bound. This makes it difficult to dissect whether the drug has altered either agonist binding or channel gating as the two processes are intimately coupled (<xref ref-type="bibr" rid="bib10">Colquhoun, 1998</xref>). This challenge has contributed to differing conclusions postulating that BZDs alter either agonist binding (<xref ref-type="bibr" rid="bib20">Goldschen-Ohm et al., 2010</xref>; <xref ref-type="bibr" rid="bib51">Perrais and Ropert, 1999</xref>; <xref ref-type="bibr" rid="bib43">Mellor and Randall, 1997</xref>; <xref ref-type="bibr" rid="bib59">Rogers et al., 1994</xref>; <xref ref-type="bibr" rid="bib73">Vicini et al., 1987</xref>), pore gating (<xref ref-type="bibr" rid="bib37">Li et al., 2013</xref>; <xref ref-type="bibr" rid="bib12">Downing et al., 2005</xref>; <xref ref-type="bibr" rid="bib7">Campo-Soria et al., 2006</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>), or an intermediate preactivation step (<xref ref-type="bibr" rid="bib21">Goldschen-Ohm et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Gielen et al., 2012</xref>). The ability of BZDs to potentiate current responses to saturating concentrations of partial agonists, and also to directly gate gain of function mutants, implies that the drug’s effect is not due to changes in binding alone. A combination of effects on both binding and gating as predicted by changes in intermediate gating steps energetically coupled with both binding sites and the pore gate is plausible (<xref ref-type="bibr" rid="bib21">Goldschen-Ohm et al., 2014</xref>). However, the molecular identity of any such intermediate states remains unclear.</p><p>Here we examined linkage between the BZD site and pore gate in isolation from any effect of the drug on agonist binding using a spontaneously active gain of function mutant (α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub>) that is directly gated by BZDs alone (<xref ref-type="bibr" rid="bib62">Scheller and Forman, 2002</xref>; <xref ref-type="bibr" rid="bib8">Chang and Weiss, 1999</xref>). In the α<sub>1</sub>L9'T background, we serially mutated each residue in the α<sub>1</sub>M2–M3 linker to alanine and assessed the effect on modulation of the channel pore by the BZD positive modulator DZ (Valium) in the absence of agonist. The M2–M3 linker is a loop following the pore lining M2 helix that together with several other important interfacial loops defines the region connecting extracellular ligand binding and transmembrane domains known to be crucially involved in the gating process of pLGICs (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Structural models show that agonist binding is associated with an outward displacement of the M2–M3 linker from the central pore axis (<xref ref-type="bibr" rid="bib46">Nemecz et al., 2016</xref>). Mutations in the linker generally impair gating by agonists (<xref ref-type="bibr" rid="bib31">Kash et al., 2003</xref>; <xref ref-type="bibr" rid="bib48">O'Shea and Harrison, 2000</xref>), and some are associated with genetic diseases such as epilepsy in GABA<sub>A</sub>Rs (<xref ref-type="bibr" rid="bib23">Hales et al., 2006</xref>; <xref ref-type="bibr" rid="bib26">Hernandez and Macdonald, 2019</xref>) or hyperekplexia in GlyRs (<xref ref-type="bibr" rid="bib4">Bode and Lynch, 2014</xref>). However, the role of the M2–M3 linker in drug modulation by BZDs is less understood.</p><p>We show that alanine substitutions throughout the α<sub>1</sub>M2–M3 linker generally impair unliganded pore gating, whereas they have little effect on the efficiency by which chemical energy from DZ binding is transmitted to the pore gate. The notable exception is α<sub>1</sub>V279A, which more than doubles DZ’s energetic contribution to pore opening, whereas larger side chains at this site do not. In a wild-type background, α<sub>1</sub>V279A enhances DZ potentiation of currents evoked by even saturating GABA, consistent with a direct effect on the pore closed/open equilibrium. Our observations identify an important residue in the α<sub>1</sub>M2–M3 linker regulating the efficiency of BZD modulation in GABA<sub>A</sub>Rs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Alanine substitutions in the α<sub>1</sub>M2–M3 linker generally impair unliganded gating</title><p>We use the gain of function mutation α<sub>1</sub>L9'T that confers spontaneous channel gating in the absence of agonist that can be further modulated by BZDs (<xref ref-type="bibr" rid="bib62">Scheller and Forman, 2002</xref>; <xref ref-type="bibr" rid="bib8">Chang and Weiss, 1999</xref>). The primary purpose for this mutation is to enable macroscopic current responses to report on pore gating by a BZD in the absence of agonist. Initially, we examine unliganded and GABA-evoked gating and in later sections turn to BZDs. In the α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub> (α<sub>1</sub>L9'T or L9'T) gain of function background, we assessed the effects of alanine substitutions in the α<sub>1</sub>M2–M3 linker on unliganded and GABA-evoked channel activity. We restricted the scan primarily to the flexible loop between helical regions associated with M2 and M3 from α<sub>1</sub>L276-T283 (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Two of these positions, α<sub>1</sub>A280 and α<sub>1</sub>A282, are natively alanine and were not mutated. Briefly, <italic>Xenopus laevis</italic> oocytes were co-injected with mRNA for α, β, and γ subunits in a 1:1:10 ratio, and current responses to microfluidic application of ligands were recorded in two-electrode voltage clamp. Each recording consisted of a series of 10 second pulses of GABA at various concentrations bookended by 10 second pulses of 1 mM picrotoxin (PTX) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Current block by the pore blocker PTX was used to assess the amount of spontaneous activity and to correct for drift or rundown over the course of the experiment (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In comparison, wild-type receptors have little to no PTX-sensitive spontaneous activity (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Normalized concentration–response relationships for the additional GABA-evoked current above the spontaneous current baseline in the L9'T background are shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. As compared to α<sub>1</sub>L9'T, all of the alanine mutations exhibited an increase in the EC<sub>50</sub> and/or steepness of the GABA concentration–response relationship (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). The increased EC<sub>50</sub> is generally consistent with previous reports of α<sub>1</sub>M2–M3 linker mutations in a wild-type background (<xref ref-type="bibr" rid="bib48">O'Shea and Harrison, 2000</xref>) and implies that side chain interactions in this region are important for channel gating by agonists. The steepness of the concentration–response relationship for α<sub>1</sub>L9'T was fairly shallow, with a hill slope slightly below one. This could reflect an increased efficiency of mono-liganded gating in the gain of function background. In such a case, the steeper hill slopes conferred by α<sub>1</sub>L276A, α<sub>1</sub>V279A, and α<sub>1</sub>Y281A may be due to a reduction in the efficiency of mono- vs di-liganded gating, although this was not verified.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Spontaneous PTX-sensitive and GABA-evoked currents for α<sub>1</sub>M2–M3 linker alanine substitutions in the gain of function α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub> background.</title><p>(Left) Summary of normalized GABA concentration–response relationships for GABA-evoked currents with the zero current baseline set to the level of spontaneous activity. Solid line is a fit of the pooled data across oocytes to <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>, and the dashed line is the fit for the L9'T background. Fit parameters are EC<sub>50</sub>, hill slope (# oocytes): L9'T = 0.25 μM, 0.83 (7); L9'T/L276A = 1.53 μM, 1.51 (4); L9'T/P277A = 1.48 μM, 0.80 (3); L9'T/K278A = 0.99 μM, 0.79 (5); L9'T/V279A = 0.23 μM, 1.44 (4); L9'T/Y281A = 0.42 μM, 1.23 (5); L9'T/T283A = 1.08 μM, 0.67 (5). Parameters for fits to individual oocytes are summarized in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>. (Right) Example currents in response to 10 second pulses of the pore blocker PTX (1 mM) or GABA (concentration in micromolar indicated above each pulse). Responses to GABA were bookended by application of PTX to assess the amount of spontaneous current and to normalize any drift or rundown during the experiment (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Correction for baseline drift and current rundown.</title><p>(<bold>A</bold>) Raw two-electrode voltage clamp current recording from α<sub>1</sub>L9'T/K278Aβ<sub>2</sub>γ<sub>2L</sub> receptors expressed in a <italic>Xenopus laevis</italic> oocyte. Responses to 10 second pulses of increasing concentrations of GABA (0.1, 1, 10, 100, and 1000 μM) were bookended by 10 second pulses of 1 mM PTX as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. (<bold>B</bold>) Baseline drift was corrected by subtracting a spline fit to selected segments of baseline (dashed line in <bold>A</bold>). (<bold>C</bold>) Current rundown was corrected by linearly scaling the current record, so that the bookending PTX responses were of equal amplitude (dotted line in <bold>B</bold>). The resulting current trace was shifted, so that zero current coincides with the peak response to block by PTX.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Summary of GABA EC<sub>50</sub> and hill slope from fitting <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> to GABA concentration–response relationships as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> for individual oocytes.</title><p>Gray box plots indicate the median and 25th and 75th percentiles. The vertical dashed line is the mean for L9'T.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Responses of wild-type α<sub>1</sub>β<sub>2</sub>γ<sub>2L</sub> receptors to 10 second pulses of either 1 mM PTX, 3 μM DZ, or 3 mM GABA.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig2-figsupp3-v2.tif"/></fig></fig-group><p>The level of unliganded channel activity was determined from the ratio of the spontaneous current amplitude as assessed by block with PTX (I<sub>PTX</sub>) to the maximal current amplitude evoked with saturating GABA (I<sub>GABA-max</sub>) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The unliganded open probability was estimated as the product of the ratio I<sub>PTX</sub>/I<sub>GABA-max</sub> and the open probability in saturating GABA (P<sub>o-GABA-max</sub>). Under the assumption that P<sub>o-GABA-max</sub> is similar for all constructs, all α<sub>1</sub>M2–M3 linker mutations except for α<sub>1</sub>P277A reduced the unliganded open probability by approximately two-fold (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). P<sub>o-GABA-max</sub> is ~0.85 in wild-type channels (<xref ref-type="bibr" rid="bib32">Keramidas and Harrison, 2010</xref>), and likely to be closer to 1.0 in a gain of function background such as α<sub>1</sub>L9'T that is further known to desensitize much more slowly than wild-type (<xref ref-type="bibr" rid="bib62">Scheller and Forman, 2002</xref>). This assumption was verified for single L9'T/V279A receptors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Thus, any reduction in P<sub>o-GABA-max</sub> for the linker mutations should only further reduce their estimated unliganded open probability. In summary, these data show that alanine mutations in the α<sub>1</sub>M2–M3 linker generally impair channel gating by increasing GABA EC<sub>50</sub> and/or reducing unliganded pore opening. This suggests that α<sub>1</sub>M2–M3 linker side chain interactions play an important role in the closed vs. open pore equilibrium even in the absence of agonist.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ratio of PTX-sensitive to maximal GABA-evoked current amplitude.</title><p>(<bold>A</bold>) Example currents from α<sub>1</sub>L9'T/V279Aβ<sub>2</sub>γ<sub>2L</sub> receptors elicited by 10 second pulses of either 1 mM PTX or 10 μM GABA. (<bold>B</bold>) Summary of the ratio of PTX-sensitive to maximal GABA-evoked current amplitude for individual oocytes. Gray box plots indicate the median and 25th and 75th percentiles. The vertical dashed line is the mean for L9'T. These ratios were estimated as being approximately proportional to the unliganded open probability by a factor that is the open probability in saturating GABA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig3-v2.tif"/></fig></sec><sec id="s2-2"><title>All but one alanine substitution in the α<sub>1</sub>M2–M3 linker have little effect on activation by DZ relative to unliganded activity</title><p>BZD positive modulators alone evoke channel opening with extremely low probability (<xref ref-type="bibr" rid="bib7">Campo-Soria et al., 2006</xref>), thus necessitating coapplication with an agonist to obtain robust currents from wild-type receptors (<xref ref-type="bibr" rid="bib17">Germann et al., 2019</xref>). However, dissecting the effects of BZDs on either agonist binding or channel gating is severely challenged in the presence of an agonist because the two processes are intimately coupled (<xref ref-type="bibr" rid="bib10">Colquhoun, 1998</xref>). To isolate effects on gating apart from any effects on agonist binding, we examined the effect of alanine substitutions in the α<sub>1</sub>M2–M3 linker on DZ-evoked currents in the background of the gain of function mutation α<sub>1</sub>L9'T in the absence of agonist. Concentration–response relationships for currents evoked by 10 second pulses of DZ were bookended by 10 second pulses of 1 mM PTX to assess spontaneous activity (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Drift or rundown was corrected as described for GABA-evoked currents (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Normalized concentration–response relationships for the additional DZ-elicited current above the spontaneous current baseline were fit to <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>. Alanine substitutions in the α<sub>1</sub>M2–M3 linker have no obvious effect on DZ concentration–response relationships with the exception of α<sub>1</sub>L276A that confers a right shift and reduction in steepness (<xref ref-type="fig" rid="fig4">Figure 4</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Reports for the EC<sub>50</sub> of DZ potentiation in wild-type receptors are similar to the DZ EC<sub>50</sub> for α<sub>1</sub>L9'T receptors reported here and in previous studies (<xref ref-type="bibr" rid="bib37">Li et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Campo-Soria et al., 2006</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>; <xref ref-type="bibr" rid="bib76">Walters et al., 2000</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Spontaneous PTX-sensitive and DZ-evoked currents for α<sub>1</sub>M2–M3 linker alanine substitutions in the gain of function α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub> background.</title><p>(Left) Summary of normalized DZ concentration–response relationships for DZ-evoked currents with the zero current baseline set to the level of spontaneous activity. Solid line is a fit of the pooled data across oocytes to <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>, and the dashed line is the fit for the L9'T background. Reduced peak responses to 10 μM DZ for L9'T/Y281A and L9'T/T283A were omitted from the fits. Fit parameters are EC<sub>50</sub>, hill slope (# oocytes): L9'T = 85 nM, 1.10 (5); L9'T/L276A = 380 nM, 0.61 (8); L9'T/P277A = 67 nM, 1.24 (5); L9'T/K278A = 72 nM, 0.97 (4); L9'T/V279A = 110 nM, 0.98 (5); L9'T/Y281A = 56 nM, 1.14 (4); L9'T/T283A = 60 nM, 1.42 (6). Parameters for fits to individual oocytes are summarized in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. (Right) Example currents in response to 10 second pulses of the pore blocker PTX (1 mM) or DZ (concentration in micromolar indicated above each pulse). Responses to DZ were bookended by application of PTX to assess the amount of spontaneous current and to normalize any drift or rundown during the experiment (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Summary of DZ EC<sub>50</sub> and hill slope from fitting <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> to DZ concentration–response relationships as shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> for individual oocytes.</title><p>Gray box plots indicate the median and 25th and 75th percentiles. The vertical dashed line is the mean for L9'T.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig4-figsupp1-v2.tif"/></fig></fig-group><p>The ratio of the maximal DZ-evoked current amplitude (I<sub>DZ-max</sub>) to PTX-sensitive current amplitude (I<sub>PTX</sub>) is a measure for how well DZ activates the channel relative to its spontaneous unliganded activity. This ratio is largely independent of alanine substitution in the α<sub>1</sub>M2–M3 linker with the notable exception of α<sub>1</sub>V279A (<xref ref-type="fig" rid="fig5">Figure 5</xref>, Table 1). Thus, apart from α<sub>1</sub>V279A, DZ-evoked currents are predictably proportional to the amount of unliganded activity. This suggests that α<sub>1</sub>V279 has a unique role in DZ modulation, whereas side chains of other linker residues are involved little or not at all.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Ratio of maximal DZ-evoked to PTX-sensitive current amplitude.</title><p>(<bold>A</bold>) Example currents from α<sub>1</sub>L9'T/K278Aβ<sub>2</sub>γ<sub>2L</sub> receptors elicited by 10 second pulses of either 1 mM PTX or 1 μM DZ. (<bold>B</bold>) Summary of the ratio of maximal DZ-evoked to PTX-sensitive current amplitude for individual oocytes. Gray box plots indicate the median and 25th and 75th percentiles. The vertical dashed line is the mean for L9'T. These ratios were used as estimates for the approximate fold-change in open probability upon DZ binding.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig5-v2.tif"/></fig></sec><sec id="s2-3"><title>Dependence of DZ gating on charge and volume at α<sub>1</sub>V279</title><p>The M2–M3 linker has both high sequence and structural similarity in pLGICs. The valine at position 279 in the GABA<sub>A</sub>R α<sub>1</sub> subunit is located near the center of the linker and is nearly always an aliphatic residue in different GABA<sub>A</sub>R subunits as well as in subunits of other pLGICs, with the exception of AChR, where it is a threonine. Even where sequences differ, structural models of the M2–M3 linker for multiple pLGICs are highly similar. To explore the side chain properties relevant to DZ gating, we examined the effect of introducing a charged aspartate or bulky tryptophan at position 279 in the α<sub>1</sub>L9'T background. We recorded unliganded PTX-sensitive and GABA- or DZ-evoked currents as described above and compared their relative current amplitudes and concentration–response relationships (<xref ref-type="fig" rid="fig6">Figure 6</xref>). The negative charge introduced by α<sub>1</sub>V279D severely inhibits unliganded gating, exhibiting very little PTX-sensitive current in relation to robust currents evoked with saturating GABA. In contrast, addition of the bulky side chain α<sub>1</sub>V279W only slightly impairs unliganded gating to a similar degree as substitution with alanine. These data suggest that side chain volume at this position is less critical for unliganded gating, whereas introduction of a negative charge nearly abolishes spontaneous activity despite the α<sub>1</sub>L9'T pore mutation. Consistent with impaired pore gating, α<sub>1</sub>V279D increases the GABA EC<sub>50</sub> by ~100-fold.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Spontaneous PTX-sensitive and GABA- or DZ-evoked currents for α<sub>1</sub>V279D and α<sub>1</sub>V279W in the gain of function α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub> background.</title><p>(<bold>A</bold>) Summary of normalized GABA concentration–response relationships for GABA-evoked currents with the zero current baseline set to the level of spontaneous activity (left). Solid line is a fit of the combined data across oocytes to <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>, and the dashed line is the fit for the L9'T background. Fit parameters are EC<sub>50</sub>, hill slope (# oocytes): L9'T/V279D = 13 μM, 0.68 (3); L9'T/V279W = 1.4 μM, 0.65 (2). Example currents in response to 10 second pulses of the pore blocker PTX (1 mM) or GABA (concentration in micromolar indicated above each pulse) (right). (<bold>B</bold>) Same as in (<bold>A</bold>) except for DZ-evoked currents. Responses from L9'T/V279D to 10 μM DZ were excluded from the fit. Fit parameters are EC<sub>50</sub>, hill slope (# oocytes): L9'T/V279D = 0.88 μM, 0.58 (3); L9'T/V279W = 0.23 μM, 0.90 (3). (<bold>C</bold>) Summary of the ratios of PTX-sensitive and either maximal GABA- or DZ-evoked current amplitudes for individual oocytes. Gray box plots indicate the median and 25th and 75th percentiles. The vertical dashed line is the mean for L9'T. These ratios were used as estimates for the approximate fold-change in open probability upon DZ binding.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig6-v2.tif"/></fig><p>The ratio of DZ-evoked to PTX-sensitive current amplitude is only slightly increased by α<sub>1</sub>V279W, whereas it is further increased by α<sub>1</sub>V279D, albeit not to the extent of α<sub>1</sub>V279A (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). However, we were unable to reach saturation for DZ-evoked currents from α<sub>1</sub>V279D due to a reduction in peak current amplitude at higher DZ concentrations consistent with occupation of a secondary lower affinity inhibitory site (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Thus, our observations for α<sub>1</sub>V279D reflect a lower limit on channel activity evoked by DZ binding. Even if α<sub>1</sub>V279D has an appreciable effect on the ratio of DZ-evoked to unliganded current, the overall effect of this mutation on channel function is likely to be dominated by its inhibition of pore gating. In contrast, α<sub>1</sub>V279W has similar effects to alanine substitutions at other linker residues. These data suggest that DZ gating is specifically enhanced by a reduction of side chain volume at position 279.</p></sec><sec id="s2-4"><title>The mutation α<sub>1</sub>V279A increases DZ’s energetic contribution to pore gating</title><p>To estimate the amount of chemical energy from DZ binding that is transmitted to the pore gate, we employed a simple model of channel gating between closed (C) and open (O) pore states in both unliganded and DZ-bound conditions (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). The model assumes that gating can be approximated with a single closed and open states in each liganded condition. The free energy differences for pore gating in unliganded (ΔG<sub>0</sub>) and DZ-bound (ΔG<sub>1</sub>) conditions were calculated according to <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2–3</xref> under the assumption that P<sub>o-GABA-max</sub> ~ 1. A comparison of ΔG<sub>0</sub> versus ΔG<sub>1</sub> shows that DZ binding confers a uniform ΔΔG<sub>DZ</sub> = ΔG<sub>1</sub>− ΔG<sub>0</sub> = −0.4 kcal/mol to the pore gating equilibrium independent of α<sub>1</sub>M2–M3 linker mutation with the notable exception f α<sub>1</sub>V279A that more than doubles ΔΔG<sub>DZ</sub> (<xref ref-type="fig" rid="fig7">Figure 7B,C</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). Importantly, this result is largely independent of our assumption for P<sub>o-GABA-max</sub> (see bold vs. light gray symbols in <xref ref-type="fig" rid="fig7">Figure 7B</xref>). Nonetheless, we verified that single L9'T/V279A channels in saturating GABA open with high probability to a similar maximal conductance level as wild-type and L9'T channels (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). These observations suggest that coupling between the BZD site and pore gate is relatively independent of individual α<sub>1</sub>M2–M3 linker side chain interactions except for α<sub>1</sub>V279, which natively hinders DZ gating as compared to its substitution with alanine. Strikingly, introduction of a bulky tryptophan or charged aspartate at position 279 have much smaller effects on ΔΔG<sub>DZ</sub>, consistent with the idea that the small side chain volume of alanine is the most relevant factor for increased DZ efficiency.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>A critical residue in the α<sub>1</sub>M2–M3 linker regulating DZ’s energetic contribution to pore gating.</title><p>(<bold>A</bold>) A simple model approximating channel gating between closed (C) and open (O) pore states in both unliganded and DZ-bound conditions. (<bold>B</bold>) Relationship between gating free energy in unliganded (ΔG<sub>0</sub>) and DZ-bound (ΔG<sub>1</sub>) conditions for α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub> receptors and α<sub>1</sub>M2–M3 linker mutations assuming P<sub>o–GABA–max </sub>= 1 (bold symbols) or P<sub>o–GABA–max </sub>= 0.5 (light gray symbols) (Equations 2–3). ΔG values are the change in energy from closed to open states, such that negative values favor opening. To illustrate this, we indicate the direction of increasing open probability (P<sub>o</sub>) along each axis. Points are the mean across oocytes. The dashed line of symmetry reflects ΔG<sub>0</sub> = ΔG<sub>1</sub> where DZ would have no effect on pore gating. The solid line is a fit to ΔG<sub>1</sub> = ΔG<sub>0</sub> + ΔΔG<sub>DZ</sub> for all of the data points except the outlier α<sub>1</sub>V279A given P<sub>o-GABA-max</sub> = 1. The good description of the data suggests that DZ’s energetic contribution to pore gating is the same for all of the constructs on this line, estimated as ΔΔG<sub>DZ</sub> = −0.4 kcal/mol. In contrast, α<sub>1</sub>V279A more than doubles the energy that DZ binding transmits to the pore gate. A comparison of the bold and light gray symbols shows that reducing P<sub>o–GABA–max</sub> to 0.5 primarily shifts the data points along the fitted line with only minor changes in ΔΔG<sub>DZ</sub>, indicating that our assumption for the value of P<sub>o–GABA–max</sub> is not critical for interpretation of ΔΔG<sub>DZ</sub>. Nonetheless, we verified that single L9'T/V279A receptors open with high probability (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). (<bold>C</bold>) Summary of ΔΔG<sub>DZ</sub> for individual oocytes. Negative values of ΔΔG<sub>DZ</sub> increase channel open probability. Gray box plots indicate the median and 25th and 75th percentiles. The vertical line is the position of linear fit in (B) corresponding to −0.4 kcal/mol.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Single-channel opening for L9'T/V279A in saturating GABA.</title><p>(Left) Single-channel recording for an α<sub>1</sub>L9'T/V279Aβ<sub>2</sub>γ<sub>2L</sub> receptor in 100 μM GABA. Dashed lines indicate fully closed (C) and fully open (O) current levels. Bottom trace shows the portion of the top trace indicated by the black bar on an expanded timescale. At least one subconductance level was observed, although it was relatively infrequent as compared to the maximal conductance level. Trace was low-pass filtered at 1 kHz for display only. (Right) Histogram of current amplitudes from the trace on the left. Solid line is a fit to a mixture of three Gaussian components, and dashed lines show individual components. Components mean ± standard deviation (weight): −2.4 ± 0.3 (0.86), −1.8 ± 0.5 (0.07), 0.0 ± 0.2 (0.07).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig7-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>The mutation α<sub>1</sub>V279A enhances DZ potentiation of GABA-evoked currents in a wild-type background</title><p>If gating in the α<sub>1</sub>L9'T background is relevant to neurotransmitter-driven gating in native receptors, then the mutation α<sub>1</sub>V279A should both impair gating by GABA and enhance DZ potentiation of GABA-evoked currents in a wild-type background. To test this, we compared GABA-evoked current responses in α<sub>1</sub>β<sub>2</sub>γ<sub>2L</sub> (wild-type) and α<sub>1</sub>V279Aβ<sub>2</sub>γ<sub>2L</sub> (V279A) receptors, as well as the ability of 1 μM DZ to potentiate these responses. First, GABA EC<sub>50</sub> is increased by α<sub>1</sub>V279A, consistent with impaired unliganded gating (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). This effect is similar, although slightly larger than previously observed in α<sub>2</sub>β<sub>1</sub>γ<sub>2S</sub> receptors (<xref ref-type="bibr" rid="bib48">O'Shea and Harrison, 2000</xref>). Second, DZ potentiates GABA-evoked peak current responses to a greater extent in V279A than in wild-type receptors, consistent with enhanced coupling between the BZD site and pore gate in the mutant (<xref ref-type="fig" rid="fig8">Figure 8B,C</xref>). In contrast to wild-type, DZ also potentiates V279A currents evoked with a saturating concentration of GABA. Together, these data suggest that the additional DZ modulation conferred by α<sub>1</sub>V279A is both independent of agonist association and additive to DZ potentiation in wild-type receptors.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>The mutation α<sub>1</sub>V279A enhances DZ potentiation of GABA-evoked current amplitudes in a wild-type (WT) α<sub>1</sub>β<sub>2</sub>γ<sub>2L</sub> background.</title><p>(<bold>A</bold>) Normalized GABA concentration–response relationships for WT (circles, three oocytes) and V279A (squares, four oocytes). Solid lines are fits to <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> for all oocytes combined. Fit parameters are EC<sub>50</sub>, hill slope (# oocytes): WT = 28 μM, 1.2 (3); V279A = 222 μM, 0.7 (4). (<bold>B</bold>) Potentiation of current amplitudes evoked by 10 second pulses of either subsaturating EC<sub>20-25</sub> (WT: 10 μM, V279A: 30 μM) or saturating EC<sub>100</sub> (WT: 3 mM, V279A: 3–30 mM) GABA by 1 μM DZ. (<bold>C</bold>) Summary of potentiation as shown in (<bold>B</bold>) for individual oocytes. For V279A EC<sub>100</sub>, squares indicate 3 or 10 mM GABA and diamonds 30 mM GABA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Reduction of GABA-evoked currents by the BZD negative modulator FG-7142 for α<sub>1</sub>β<sub>2</sub>γ<sub>2L</sub> (WT) and α<sub>1</sub>V279Aβ<sub>2</sub>γ<sub>2L</sub> (V279A) receptors.</title><p>(<bold>A</bold>) Pair of current responses to 10 second pulses of ~EC<sub>20-25</sub> GABA (WT: 10 μM, V279A: 30 μM) followed by a pair of responses to ~EC<sub>20-25</sub> GABA + 1 μM FG-7142. (<bold>B</bold>) Summary of the ratio of peak currents as shown in (<bold>A</bold>) in the presence and absence of FG-7142 for individual oocytes. Gray box plots indicate the median and 25th and 75th percentiles.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig8-figsupp1-v2.tif"/></fig></fig-group><p>In addition to the BZD positive modulator DZ, we examined the effect of the α<sub>1</sub>V279A mutation on the BZD negative modulator FG-7142 (<xref ref-type="bibr" rid="bib27">Im et al., 1995</xref>). Responses to ~EC<sub>20-25</sub> GABA were reduced in the presence of FG-7142 in both WT and V279A receptors, but to a slightly lesser extent in V279A (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). Distinct mechanisms for BZD positive and negative modulation could explain the observed reduction in negative modulation as compared to enhancement of positive modulation conferred by α<sub>1</sub>V279A. Alternatively, our observations are also consistent with the idea that α<sub>1</sub>V279A stabilizes an open channel configuration specifically in the BZD-bound complex and that this stabilization works in concert with positive modulators but hinders negative modulators.</p></sec><sec id="s2-6"><title>α<sub>1</sub>L9'T and α<sub>1</sub>V279A have independent and additive effects on the pore-gating equilibrium</title><p>To further explore the idea that α<sub>1</sub>V279A confers its effects primarily by altering pore gating in DZ-bound receptors, we asked whether a simple Monod–Wyman–Changeux (MWC) model of receptor behavior can account for our observations (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). This model has been widely used to describe pseudo-steady-state behavior in GABA<sub>A</sub> receptors (<xref ref-type="bibr" rid="bib70">Steinbach and Akk, 2019</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>; <xref ref-type="bibr" rid="bib8">Chang and Weiss, 1999</xref>). For comparison with model simulations, we estimated open probability (P<sub>o</sub>) as a function of GABA or DZ concentration (black curves in <xref ref-type="fig" rid="fig9">Figure 9B</xref>) from fits of <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> to the data shown in <xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig4">4,</xref> and <xref ref-type="fig" rid="fig8">8</xref> where the minimum and maximum P<sub>o</sub> were scaled according to our observed PTX-sensitive and GABA- or DZ-evoked current amplitudes. In the α<sub>1</sub>L9'T background, the maximum GABA-evoked P<sub>o</sub> was allowed to vary during optimization, and the minimum unliganded P<sub>o</sub> was scaled relative to the maximum by the observed mean ratio of I<sub>PTX</sub>/I<sub>GABA-max</sub> (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The maximum DZ-evoked P<sub>o</sub> was scaled relative to the minimum unliganded P<sub>o</sub> by the observed mean ratio of I<sub>DZ-max</sub>/I<sub>PTX</sub> (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The maximal P<sub>o</sub> was set to 0.85 for α<sub>1</sub>β<sub>2</sub>γ<sub>2L</sub> receptors (<xref ref-type="bibr" rid="bib32">Keramidas and Harrison, 2010</xref>) and allowed to vary for α<sub>1</sub>V279Aβ<sub>2</sub>γ<sub>2L</sub> receptors.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>A simple MWC model of channel gating largely accounts for the observed effects of α<sub>1</sub>L9'T and α<sub>1</sub>V279A via independent and additive effects on the pore-gating equilibrium.</title><p>(<bold>A</bold>) The model depicts channel gating between closed (C) and open (O) states with independent binding of two GABA (G) and one DZ (D) molecule. L is the ratio of closed to open state probabilities in the absence of ligand, K<sub>G</sub> and K<sub>D</sub> are the respective dissociation constants for GABA or DZ, and c and d are the respective factors by which GABA or DZ binding influence channel opening. The probability to be in an open state is given by <xref ref-type="disp-formula" rid="equ4">Equation 4</xref>. (<bold>B</bold>) Estimated open probability (P<sub>o</sub>) from the data in <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig5">5</xref> (black) overlaid with model simulations (<xref ref-type="disp-formula" rid="equ4">Equation 4</xref>, red). See main text for a detailed description. Model parameters are: L<sub>L9'T</sub> = 1.8; L<sub>L9'T/V279A</sub> = 4.4; L<sub>WT</sub> = 18000; K<sub>G</sub> = 53 μM; K<sub>D</sub> = 180 nM; c = 0.0031; d = 0.59; d<sub>V279A</sub> = 0.20. (<bold>C</bold>) The model’s prediction for potentiation of WT and V279A GABA-evoked responses by 1μM DZ.</p><p> <supplementary-material id="fig9scode1"><label>Figure 9—source code 1.</label><caption><title>MWC simulation code.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64400-fig9-code1-v2.zip"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Estimated open probability (P<sub>o</sub>) from the data in <xref ref-type="fig" rid="fig2">Figure 2</xref> (black) overlaid with simulations for the model in <xref ref-type="fig" rid="fig9">Figure 9A</xref> (red).</title><p>(<bold>A</bold>) Model fits assuming mutations have identical affinities for GABA (K<sub>G</sub> = 190 μM, c constrained to 0.003). L9'T: L = 1.5; L9'T/L276A: L = 0.9; L9'T/P277A: L = 1.3; L9'T/K278A: L = 3.9; L9'T/V279A: L = 0.7; L9'T/Y281A: L = 2.6; L9'T/T283A: L = 6.3. (<bold>B</bold>) Model fits with constraints L =(1 – P<sub>o–unliganded</sub>)/P<sub>o–unliganded</sub> and c = 0.003. L9'T: K<sub>G</sub> = 90 μM; L9'T/L276A: K<sub>G</sub> = 390 μM; L9'T/P277A: K<sub>G</sub> = 670 μM; L9'T/K278A: K<sub>G</sub> = 240 μM; L9'T/V279A: K<sub>G</sub> = 50 μM; L9'T/Y281A: K<sub>G</sub> = 120 μM; L9'T/T283A: K<sub>G</sub> = 180 μM. (<bold>C</bold>) Same as (<bold>B</bold>) except c was allowed to vary. L9'T: K<sub>G</sub> = 270 μM, c = 0.001; L9'T/L276A: K<sub>G</sub> = 250 μM, c = 0.005; L9'T/P277A: K<sub>G</sub> = 500 μM, c = 0.004; L9'T/K278A: K<sub>G</sub> = 8 μM, c = 0.07; L9'T/V279A: K<sub>G</sub> = 3 μM, c = 0.04; L9'T/Y281A: K<sub>G</sub> = 270 μM, c = 0.001; L9'T/T283A: K<sub>G</sub> = 5 μM, c = 0.07.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64400-fig9-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Summary of peak current ratios and ΔΔG<sub>DZ</sub> for mutations in the L9'T background.</title><p>Data are mean ± standard deviation (# oocytes), and individual data points are shown in <xref ref-type="fig" rid="fig3">Figures 3B</xref>, <xref ref-type="fig" rid="fig5">5B</xref>, <xref ref-type="fig" rid="fig6">6C,</xref> and <xref ref-type="fig" rid="fig7">7C</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>I<sub>PTX</sub> /I<sub>GABA-max</sub></th><th>I<sub>DZ-max</sub> /I<sub>PTX</sub></th><th>ΔΔG<sub>DZ</sub> (kcal/mol)</th></tr></thead><tbody><tr><td>L9'T</td><td>0.36 ± 0.04 (5)</td><td>1.35 ± 0.05 (5)</td><td>−0.31 ± 0.04 (5)</td></tr><tr><td>L9'T/L276A</td><td>0.22 ± 0.09 (4)</td><td>1.62 ± 0.07 (5)</td><td>−0.45 ± 0.04 (5)</td></tr><tr><td>L9'T/P277A</td><td>0.45 ± 0.03 (3)</td><td>1.41 ± 0.17 (5)</td><td>−0.46 ± 0.20 (5)</td></tr><tr><td>L9'T/K278A</td><td>0.20 ± 0.06 (5)</td><td>1.67 ± 0.15 (4)</td><td>−0.44 ± 0.08 (4)</td></tr><tr><td>L9'T/V279A</td><td>0.17 ± 0.04 (4)</td><td>3.30 ± 0.70 (5)</td><td>−1.11 ± 0.30 (5)</td></tr><tr><td>L9'T/V279D</td><td>0.02 ± 0.005 (3)</td><td>2.31 ± 0.08 (3)</td><td>−0.52 ± 0.02 (3)</td></tr><tr><td>L9'T/V279W</td><td>0.16 ± 0.05 (2)</td><td>1.96 ± 0.23 (3)</td><td>−0.53 ± 0.10 (3)</td></tr><tr><td>L9'T/Y281A</td><td>0.25 ± 0.07 (5)</td><td>1.59 ± 0.11 (4)</td><td>−0.42 ± 0.07 (4)</td></tr><tr><td>L9'T/T283A</td><td>0.11 ± 0.03 (5)</td><td>1.71 ± 0.10 (6)</td><td>−0.38 ± 0.04 (6)</td></tr></tbody></table></table-wrap><p>The model assumes independent GABA and DZ binding. Model parameters were optimized by globally minimizing the sum of squared residuals between simulated (<xref ref-type="disp-formula" rid="equ4">Equation 4</xref>) and estimated P<sub>o</sub> as a function of GABA or DZ concentration for α<sub>1</sub>L9'Tβ<sub>2</sub>γ<sub>2L</sub>, α<sub>1</sub>L9'T/V279Aβ<sub>2</sub>γ<sub>2L</sub>, and α<sub>1</sub>β<sub>2</sub>γ<sub>2L</sub> receptors (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). Responses to α<sub>1</sub>V279Aβ<sub>2</sub>γ<sub>2L</sub> receptors were not considered during optimization and treated as a model prediction. The mutations α<sub>1</sub>L9'T and α<sub>1</sub>V279A were allowed to perturb the parameter L with the assumption that their effects are independent in the L9'T/V279A double mutant. For wild-type receptors, L was fixed according to its approximate relation with EC<sub>50</sub> as <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mn>9</mml:mn><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>L</mml:mi><mml:mn>9</mml:mn><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib70">Steinbach and Akk, 2019</xref>; <xref ref-type="bibr" rid="bib2">Akk et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Scheller and Forman, 2002</xref>; <xref ref-type="bibr" rid="bib8">Chang and Weiss, 1999</xref>). The value of d was assumed to be the same for L9'T and wild-type receptors and allowed to vary in the presence of the α<sub>1</sub>V279A mutation. The resulting optimized model parameters (<xref ref-type="fig" rid="fig9">Figure 9</xref> caption) were highly constrained by the data (i.e. estimated P<sub>o</sub>), and the model does a fairly good job of describing our observed responses to either GABA or DZ, differing somewhat in the steepness of their concentration dependence (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). Furthermore, the model qualitatively accounts for observations from α<sub>1</sub>V279Aβ<sub>2</sub>γ<sub>2L</sub> receptors even though they were not considered during optimization. The model’s predicted maximum P<sub>o</sub> approached 1.0 in the α<sub>1</sub>L9'T background, consistent with a gain of function phenotype. In contrast, maximal P<sub>o</sub> was reduced in α<sub>1</sub>V279Aβ<sub>2</sub>γ<sub>2L</sub> as compared to wild-type receptors, as expected for a reduction in unliganded activity. These results suggest that α<sub>1</sub>L9'T and α<sub>1</sub>V279A have independent and additive effects on the gating equilibrium, and that for α<sub>1</sub>V279A, this effect depends on DZ occupancy.</p><p>Although responses to GABA or DZ alone are largely explained by this model, DZ potentiation of GABA-evoked responses in a wild-type background is either underestimated or overestimated for subsaturating or saturating GABA concentrations, respectively (<xref ref-type="fig" rid="fig9">Figure 9C</xref>). Previous applications of this model to BZD modulation in gain of function backgrounds predict a larger left shift of the P<sub>o</sub> curve in the presence of drug more similar to that observed, in part due to a smaller value of d (<xref ref-type="bibr" rid="bib7">Campo-Soria et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Downing et al., 2005</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>). However, reducing d also enhances the predicted potentiation of responses to saturating GABA, contrary to that observed for wild-type receptors. Thus, the model is either too simplistic or its assumptions too strict to describe all aspects of DZ potentiation in wild-type channels that both rapidly desensitize and may involve drug modulation of agonist binding and/or intermediate gating steps (<xref ref-type="bibr" rid="bib21">Goldschen-Ohm et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Gielen et al., 2012</xref>). Nonetheless, the model does predict an increase in DZ potentiation of responses evoked by both subsaturating and saturating GABA for α<sub>1</sub>V279A, qualitatively similar to that observed. For responses to saturating GABA in V279A, 42% of the predicted potentiation is accounted for by the lower P<sub>o-GABA-max</sub> as compared to WT, and the remainder reflects the mutations enhancement of DZ gating.</p></sec><sec id="s2-7"><title>Effects of alanine mutations on gating by GABA</title><p>To explore the effects of the mutations on gating by GABA, we fit estimated open probability versus GABA concentration relationships using the model in <xref ref-type="fig" rid="fig9">Figure 9A</xref> (front face only in the absence of DZ). Estimated open probabilities from fits of <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> to the data in <xref ref-type="fig" rid="fig2">Figure 2</xref> were scaled according to the assumption that P<sub>o-GABA-max </sub>= 1 as described above. We first asked whether all of the mutations could be explained solely by differences in their intrinsic closed–open equilibrium (parameter L). <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref> shows model predictions where all constructs share identical affinities for GABA (i.e. parameters K<sub>G</sub> and c). The overall rough qualitative agreement with the data suggests that differences in unliganded open probability are likely to account for much of the observed effects. For comparison, we next constrained L based on the estimated unliganded P<sub>o</sub> as L = (1 − P<sub>o</sub>)/P<sub>o</sub> and allowed GABA affinity to differ across constructs. The resulting model fits were slightly improved to a nearly equivalent extent regardless of whether the relative affinity for closed versus open states (parameter c) was held constant (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B</xref>) or allowed to vary (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1C</xref>). Thus, the simplest conclusion is that mutations with right-shifted EC<sub>50</sub>s reduce GABA affinity for the closed state, although we cannot rule out compensatory changes in affinity for closed and open states.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The main conclusions of this study are as follows: First, in the α<sub>1</sub>L9'T gain of function background alanine substitutions in the α<sub>1</sub>M2–M3 linker generally impair unliganded pore opening, indicating that side chain interactions with the linker are important for gating even in the absence of bound agonist. Second, the same mutations have no effect on the amount of chemical energy from DZ binding transmitted to the pore gate, except for α<sub>1</sub>V279A which more than doubles DZ’s energetic contribution to pore gating. Thus, α<sub>1</sub>V279 plays a crucial role to natively hinder drug modulation as compared to its substitution with alanine. Third, introduction of a bulky tryptophan or charged aspartate at position 279 is less favorable than the smaller alanine, suggesting that DZ modulation is inhibited by side chain interactions at the center of the linker. Fourth, α<sub>1</sub>V279D severely impairs unliganded gating. Fifth, α<sub>1</sub>V279A similarly enhances DZ potentiation of GABA-evoked currents in a wild-type background. Sixth, the effects of α<sub>1</sub>V279A in both α<sub>1</sub>L9'T and wild-type backgrounds are explained by specific changes in the pore gating equilibrium and its coupling to DZ binding at the BZD site.</p><p>The use of gain of function mutations to study modulatory or weakly activating ligands is well appreciated (<xref ref-type="bibr" rid="bib17">Germann et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Akk et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Campo-Soria et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Downing et al., 2005</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>; <xref ref-type="bibr" rid="bib14">Findlay et al., 2001</xref>). Single-channel gating dynamics for combinations of gain of function mutations in AChR suggest that the unliganded and agonist-bound gating mechanisms are similar if not identical and also that they are similarly affected by mutations (<xref ref-type="bibr" rid="bib57">Purohit and Auerbach, 2009</xref>). Consistent with this idea, MWC models of pseudo steady-state GABA<sub>A</sub>R function have been largely successful in describing the effects of gain of function mutations with changes to the pore gating equilibrium independent of agonist binding (<xref ref-type="bibr" rid="bib70">Steinbach and Akk, 2019</xref>; <xref ref-type="bibr" rid="bib12">Downing et al., 2005</xref>; <xref ref-type="bibr" rid="bib7">Campo-Soria et al., 2006</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>; <xref ref-type="bibr" rid="bib8">Chang and Weiss, 1999</xref>). The model reported here in <xref ref-type="fig" rid="fig9">Figure 9</xref> supports this conclusion.</p><p>Although the effects of α<sub>1</sub>V279A can also be explained by specific changes to the pore-gating equilibrium, they are dependent on DZ occupation of the BZD site. From the model in <xref ref-type="fig" rid="fig9">Figure 9A</xref>, we compute an efficiency for GABA of <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>G</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mi>G</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi><mml:mo>=</mml:mo><mml:mn>37</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, similar to that reported previously (<xref ref-type="bibr" rid="bib45">Nayak et al., 2019</xref>). In contrast, DZ efficiency is <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>Z</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. Whereas α<sub>1</sub>V279A decreases unliganded pore opening, it also increases DZ efficiency (<inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>,</mml:mo><mml:mi>V</mml:mi><mml:mn>279</mml:mn><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>9</mml:mn><mml:mi>%</mml:mi></mml:math></inline-formula>) to the extent that DZ binding overcomes its intrinsic inhibitory effect and results in similar or even enhanced activation as compared to wild type (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Interestingly, an M2–M3 linker mutation in the γ<sub>2</sub> subunit was similarly observed to impair activation by GABA and enhance modulation by the general anesthetic propofol (<xref ref-type="bibr" rid="bib47">O'Shea et al., 2009</xref>).</p><p>Our estimates for the energetic effect of DZ binding on pore gating (−0.4 kcal/mol) are similar to prior estimates from direct gating in L9'S/T backgrounds and from kinetic models (<xref ref-type="bibr" rid="bib21">Goldschen-Ohm et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Gielen et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Downing et al., 2005</xref>; <xref ref-type="bibr" rid="bib61">Rüsch and Forman, 2005</xref>). This is approximately 10-fold less than the energy derived from binding each molecule of GABA (<xref ref-type="bibr" rid="bib21">Goldschen-Ohm et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Maksay, 1994</xref>; <xref ref-type="bibr" rid="bib28">Jackson, 1992</xref>). However, it is sufficient to produce a relevant change in open probability in channels with small free energy differences between closed and open states, such as conferred by single bound agonists, partial agonists, other allosteric modulators, or gain of function mutations. From a clinical perspective, such small perturbations are likely to be more easily tolerated in patients. Given that the M2–M3 linker is associated with early movements during AChR activation (<xref ref-type="bibr" rid="bib56">Purohit et al., 2013</xref>), it is possible that biasing the linker toward its active conformation in the α<sub>1</sub>L9'T background could limit our ability to observe its full range of motion. In this case, our observed effects of linker mutations on DZ modulation may underestimate their effects on the full activation pathway.</p><p>The interface between the extracellular agonist- and BZD-binding domains and the transmembrane helices is formed largely by several loops including the M2–M3 linker, Cys loop, β1–β2 loop and β8–β9 linker, and pre-M1 segment from neighboring subunits (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Mutagenesis suggests that interactions between these domains are important for channel gating by agonists (<xref ref-type="bibr" rid="bib31">Kash et al., 2003</xref>; <xref ref-type="bibr" rid="bib48">O'Shea and Harrison, 2000</xref>) thought to involve an outward radial displacement of the M2–M3 linker (<xref ref-type="bibr" rid="bib46">Nemecz et al., 2016</xref>). Rate versus free energy linear relationships in AChR suggest that the M2–M3 linker moves early during channel activation, similar to rearrangements at agonist binding sites (<xref ref-type="bibr" rid="bib56">Purohit et al., 2013</xref>). Consistent with these observations, mutant cycle analysis indicates strong long-range coupling between residues in the M2–M3 linker and agonist binding sites (<xref ref-type="bibr" rid="bib22">Gupta et al., 2017</xref>). Given the homology between the BZD site at the α/γ interface and agonist sites at β/α interfaces, interactions between the M2–M3 linker and BZD site are reasonable, although they need not be very strong given the relatively small energy DZ contributes to pore gating. As with agonist sites, such interactions could be mediated by global backbone conformational fluctuations or via distinct structural components, or both. Either way, side chain interactions at position 279 in the α<sub>1</sub> subunit play an important role in coupling between the BZD site and pore gate.</p><p>In structural models, the M2–M3 linker adopts a C-shaped conformation with α<sub>1</sub>V279 oriented inwards toward the center of the arc (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="bibr" rid="bib33">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Laverty et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Masiulis et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Phulera et al., 2018</xref>; <xref ref-type="bibr" rid="bib78">Zhu et al., 2018</xref>). We hypothesize that the side chain at position 279 is centrally involved in steric interactions between linker residues near the top of the M2 and M3 helices. Removing this obstruction (α<sub>1</sub>V279A) would allow the linker to become more compact and bring the M2 and M3 helices closer together. In contrast, similar or larger side chains (α<sub>1</sub>V279D/W) would sterically inhibit such a conformational change. In this case, we speculate that the closer proximity of the M3 helix could impair unliganded pore gating by hindering radial expansion of the pore lining M2 helix. Conversely, a more compact transmembrane domain may also enhance coupling with the BZD site (<xref ref-type="bibr" rid="bib33">Kim et al., 2020</xref>). Valine and threonine residues in GlyR and AchR aligning with V279 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) adopt a similar conformation (<xref ref-type="bibr" rid="bib35">Kumar et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Nemecz et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">Du et al., 2015</xref>), suggesting that this residue has a conserved role in other pLGICs.</p><p>Alternatively, removing most of the central side chain may simply alter linker flexibility. Linker flexibility has been suggested to be inversely correlated with gating, where stabilizing interactions between α<sub>1</sub>R19' (located just below α<sub>1</sub>V279) and the linker backbone may promote coupling between extracellular and intracellular domains (<xref ref-type="bibr" rid="bib41">Masiulis et al., 2019</xref>). Thus, the strong inhibition of unliganded opening conferred by α<sub>1</sub>V279D could reflect competition for α<sub>1</sub>R19', thereby weakening its interaction with the linker backbone and increasing linker flexibility. However, this does not provide a simple explanation for the opposing effects of α<sub>1</sub>V279A on unliganded versus DZ-bound gating. Regardless, it is important to keep in mind that the energetic changes that we observe for DZ gating are on the order of a hydrogen bond or two, and thus can be accounted for by relatively subtle changes.</p><p>The β8-β9 linker and pre-M1 in the neighboring γ<sub>2</sub> subunit come in close proximity to the α<sub>1</sub>M2–M3 linker and are known to be important for BZD modulation, with the β8-β9 linker also contributing to the BZD-binding site (<xref ref-type="bibr" rid="bib25">Hanson and Czajkowski, 2011</xref>; <xref ref-type="bibr" rid="bib24">Hanson and Czajkowski, 2008</xref>). In AChR strong coupling with the adjacent β8-β9 linker and pre-M1 segment of the neighboring subunit occurs primarily via the threonine aligning with α<sub>1</sub>V279 in GABA<sub>A</sub>R and its neighboring serine (<xref ref-type="bibr" rid="bib22">Gupta et al., 2017</xref>). A reorientation of the linker due to removal of steric interactions near its center could alter coupling to the BZD site via interactions with the γ<sub>2</sub> β8-β9 linker and/or pre-M1. For example, a compression of the ends of the M2–M3 linker would cause the middle of the linker to be squeezed outward toward the neighboring γ<sub>2</sub> subunit, potentially enhancing intersubunit coupling. Comparison of GlyR structures in apo or antagonist-bound versus agonist-bound conformations indicates that intersubunit interactions between the M2–M3 linker in the vicinity of the valine aligning with V279 and the following serine, and the top of the M1 helix in the adjacent subunit are weakened during channel activation (<xref ref-type="bibr" rid="bib13">Du et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Kumar et al., 2020</xref>). Thus, a stronger intersubunit coupling in this area could potentially both reduce unliganded opening and enhance coupling with rearrangements of the γ<sub>2</sub> subunit upon BZD binding. However, other regions including the β4-β5 linker in the channel’s outer vestibule also affect BZD modulation of agonist-evoked currents (<xref ref-type="bibr" rid="bib52">Pflanz et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Venkatachalan and Czajkowski, 2012</xref>). Thus, BZD modulation likely involves larger domain fluctuations in addition to any specific molecular pathways involving α<sub>1</sub>V279.</p><p>Recent structures of αβγ receptors show DZ bound not only at the classical α/γ site in the extracellular domain, but also in the transmembrane domain below the M2–M3 linker at β/α and γ/β intersubunit interfaces (<xref ref-type="bibr" rid="bib33">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Masiulis et al., 2019</xref>). Thus, it is intriguing to speculate that enhanced DZ gating as conferred by α<sub>1</sub>V279A may involve occupation of a transmembrane site. However, these structures were solved in the presence of 100–200 μM DZ, and the relevance of these transmembrane sites to high affinity binding of ~1 μM DZ at the classical site is unclear (<xref ref-type="bibr" rid="bib76">Walters et al., 2000</xref>). Also, DZ binding in the transmembrane domain was not observed at α/γ or α/β interfaces. Therefore, we favor the interpretation that our observed effects reflect altered functional coupling with the classical site.</p><p>Our observations reveal a critical residue V279 in the α<sub>1</sub>M2–M3 linker, which regulates energetic coupling between the BZD site and the pore gate, whereas other linker side chains contribute little or not at all. These data shed new light on the molecular basis for GABA<sub>A</sub>R modulation by one of the most widely prescribed classes of psychotropic drugs.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mutagenesis and expression in oocytes</title><p>DNA for wild-type GABA<sub>A</sub>R rat α<sub>1</sub>, β<sub>2</sub>, and γ<sub>2L</sub> subunits were a gift from Dr. Cynthia Czajkowski. Single alanine substitutions were introduced throughout the α<sub>1</sub>M2–M3 linker from L276-T283 in addition to the gain of function α<sub>1</sub>L9'T pore mutation (rat α<sub>1</sub>L263T) (QuikChange II, Qiagen). Mutations V279D and V279W were introduced similarly. Each construct was verified by forward and reverse sequencing of the entire gene. mRNA for each construct was generated (mMessage mMachine T7, Ambion) for expression in <italic>X. laevis</italic> oocytes (EcoCyte Bioscience, Austin, TX). Oocytes were injected with 27–54 ng of total mRNA for α, β, and γ subunits in a 1:1:10 ratio (<xref ref-type="bibr" rid="bib5">Boileau et al., 2002</xref>) (Nanoject, Drummond Scientific). Oocytes were incubated in ND96 (in mM: 96 NaCl, 2 KCl, 1 MgCl<sub>2</sub>, 1.8 CaCl<sub>2</sub>, 5 HEPES, pH 7.2) with 100 mg/ml gentamicin at 18°C.</p></sec><sec id="s4-2"><title>Two-electrode voltage clamp recording and analysis</title><p>Currents from expressed channels 1–3 days post-injection were recorded in two-electrode voltage clamp (Dagan TEV-200, HEKA ITC and Patchmaster software). Oocytes were held at −80 mV and perfused continuously with buffer (ND96) or buffer containing PTX, GABA, or DZ. PTX was diluted from a 1 M stock solution in DMSO. DZ was diluted from a 10 mM stock solution in DMSO. Fresh PTX and DZ stock solutions were tested several times with no change in results. GABA was dissolved directly from powder. A microfluidic pump (Elveflow OB1 MK3+) and rotary valve (Elveflow MUX Distributor) provided consistent and repeatable perfusion and solution exchange across experiments, which limited solution exchange variability to primarily differences between oocytes only. Ten second pulses of PTX, GABA, or DZ were followed by 3–6 min in buffer to allow currents to return to baseline. Recorded currents were analyzed with custom scripts in MATLAB (Mathworks). Recordings of concentration–response relationships were bookended by pulses of PTX to correct for any drift or rundown during the experiment. Briefly, currents were baseline subtracted to correct for drift and then scaled by a linear fit to the peak of each PTX response to correct for rundown (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The amount of current rundown was variable across oocytes, with no clear relation to specific constructs. Concentration–response relationships were fit to the Hill equation:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mfrac><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p> where <inline-formula><mml:math id="inf5"><mml:mi>I</mml:mi></mml:math></inline-formula> is the peak current response, <inline-formula><mml:math id="inf6"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> is ligand concentration, <inline-formula><mml:math id="inf7"><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the concentration eliciting a half-maximal response, and <inline-formula><mml:math id="inf8"><mml:mi>n</mml:mi></mml:math></inline-formula> is the Hill slope.</p></sec><sec id="s4-3"><title>Single-channel recording</title><p>HEK293T cells were transfected with DNA for rat α<sub>1</sub>L9'T/V279A, β<sub>2</sub> and γ<sub>2L</sub> subunits in a 1:1:1 ratio. Single-channel currents were recorded 16–32 hr post-transfection from excised inside-out patches clamped at −80 mV. Currents were acquired at 20 kHz and low-pass filtered at 2 kHz (Axopatch 200A, HEKA ITC, and PatchMaster software). Extracellular (pipet) solution was (in mM): 145 NaCl, 2.5 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 4 Dextrose, pH 7.3 with NaOH. Intracellular (bath) solution was (in mM): 140 KCl, 10 EGTA, 10 HEPES, 2 MgATP, pH 7.3 with KOH. GABA was dissolved in the extracellular solution.</p></sec><sec id="s4-4"><title>DZ-gating model</title><p>For the model in <xref ref-type="fig" rid="fig7">Figure 7A</xref>, the free energy difference for unliganded (ΔG<sub>0</sub>) and DZ-bound (ΔG<sub>1</sub>) gating was estimated as follows:<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mo>−</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mi>X</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mo>−</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mi>X</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>−</mml:mo><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>T</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mo>−</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mo>−</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mi>X</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> are as shown in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig5">5</xref>, <italic>k</italic> is the Boltzmann constant, <italic>T</italic> is temperature, and <inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mo>-</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the open probability in saturating GABA, which was assumed to be approximately 1. Importantly, even if this assumption is incorrect, the effect on DZ’s energetic contribution to pore gating should be minimal and our overall conclusion unchanged (see <xref ref-type="fig" rid="fig7">Figure 7B</xref>). Also, this assumption was verified for single L9'T/V279A receptors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>).</p></sec><sec id="s4-5"><title>MWC model</title><p>For the model in <xref ref-type="fig" rid="fig9">Figure 9A</xref>, the probability to be in an open (O) state is given by:<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>L</mml:mi><mml:mfrac><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi>D</mml:mi><mml:mi>Z</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></disp-formula>where L is the ratio of closed (C) to open (O) state probabilities in the absence of ligand, K<sub>G</sub> and K<sub>D</sub> are the respective dissociation constants for GABA or DZ, and c and d are the respective factors by which GABA or DZ binding influence pore opening.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Cynthia Czajkowski for gifting DNA for wild-type GABA<sub>A</sub>R subunits, and Drs. Richard Aldrich and Eric Senning for helpful discussions and shared use of equipment.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Visualization, Methodology, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-64400-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Source code for the modeling depicted in Figure 9 has been provided.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname> <given-names>SD</given-names></name><name><surname>Landon</surname> <given-names>BE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Patterns in outpatient benzodiazepine prescribing in the United States</article-title><source>JAMA Network Open</source><volume>2</volume><elocation-id>e187399</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.7399</pub-id><pub-id pub-id-type="pmid">30681713</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akk</surname> <given-names>G</given-names></name><name><surname>Shin</surname> <given-names>DJ</given-names></name><name><surname>Germann</surname> <given-names>AL</given-names></name><name><surname>Steinbach</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GABA type A receptor activation in the allosteric coagonist model framework: relationship between EC<sub>50</sub> and basal activity</article-title><source>Molecular Pharmacology</source><volume>93</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1124/mol.117.110569</pub-id><pub-id pub-id-type="pmid">29150461</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachhuber</surname> <given-names>MA</given-names></name><name><surname>Hennessy</surname> <given-names>S</given-names></name><name><surname>Cunningham</surname> <given-names>CO</given-names></name><name><surname>Starrels</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013</article-title><source>American Journal of Public Health</source><volume>106</volume><fpage>686</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2016.303061</pub-id><pub-id pub-id-type="pmid">26890165</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode</surname> <given-names>A</given-names></name><name><surname>Lynch</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The impact of human hyperekplexia mutations on glycine receptor structure and function</article-title><source>Molecular Brain</source><volume>7</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/1756-6606-7-2</pub-id><pub-id pub-id-type="pmid">24405574</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boileau</surname> <given-names>AJ</given-names></name><name><surname>Baur</surname> <given-names>R</given-names></name><name><surname>Sharkey</surname> <given-names>LM</given-names></name><name><surname>Sigel</surname> <given-names>E</given-names></name><name><surname>Czajkowski</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The relative amount of cRNA coding for gamma2 subunits affects stimulation by benzodiazepines in GABA(A) receptors expressed in <italic>Xenopus</italic> oocytes</article-title><source>Neuropharmacology</source><volume>43</volume><fpage>695</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(02)00036-9</pub-id><pub-id pub-id-type="pmid">12367615</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braat</surname> <given-names>S</given-names></name><name><surname>Kooy</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The GABAA receptor as a therapeutic target for neurodevelopmental disorders</article-title><source>Neuron</source><volume>86</volume><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.042</pub-id><pub-id pub-id-type="pmid">26050032</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campo-Soria</surname> <given-names>C</given-names></name><name><surname>Chang</surname> <given-names>Y</given-names></name><name><surname>Weiss</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mechanism of action of benzodiazepines on GABA<sub>A</sub> receptors</article-title><source>British Journal of Pharmacology</source><volume>148</volume><fpage>984</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706796</pub-id><pub-id pub-id-type="pmid">16783415</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>Y</given-names></name><name><surname>Weiss</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Allosteric activation mechanism of the alpha 1 beta 2 gamma 2 gamma-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine</article-title><source>Biophysical Journal</source><volume>77</volume><fpage>2542</fpage><lpage>2551</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(99)77089-X</pub-id><pub-id pub-id-type="pmid">10545355</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname> <given-names>S</given-names></name><name><surname>Chanda</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Free-energy relationships in ion channels activated by voltage and ligand</article-title><source>Journal of General Physiology</source><volume>141</volume><fpage>11</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1085/jgp.201210860</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colquhoun</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors</article-title><source>British Journal of Pharmacology</source><volume>125</volume><fpage>923</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0702164</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname> <given-names>CN</given-names></name><name><surname>Wafford</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function</article-title><source>Biochemical Society Transactions</source><volume>32</volume><fpage>529</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1042/bst0320529</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downing</surname> <given-names>SS</given-names></name><name><surname>Lee</surname> <given-names>YT</given-names></name><name><surname>Farb</surname> <given-names>DH</given-names></name><name><surname>Gibbs</surname> <given-names>TT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA(A) receptors supports an allosteric model of modulation</article-title><source>British Journal of Pharmacology</source><volume>145</volume><fpage>894</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706251</pub-id><pub-id pub-id-type="pmid">15912137</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>J</given-names></name><name><surname>Lü</surname> <given-names>W</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Gouaux</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glycine receptor mechanism elucidated by electron cryo-microscopy</article-title><source>Nature</source><volume>526</volume><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/nature14853</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Findlay</surname> <given-names>GS</given-names></name><name><surname>Ueno</surname> <given-names>S</given-names></name><name><surname>Harrison</surname> <given-names>NL</given-names></name><name><surname>Harris</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Allosteric modulation in spontaneously active mutant γ-aminobutyric acidA receptors</article-title><source>Neuroscience Letters</source><volume>305</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(01)01646-9</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fluyau</surname> <given-names>D</given-names></name><name><surname>Revadigar</surname> <given-names>N</given-names></name><name><surname>Manobianco</surname> <given-names>BE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation</article-title><source>Therapeutic Advances in Psychopharmacology</source><volume>8</volume><fpage>147</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1177/2045125317753340</pub-id><pub-id pub-id-type="pmid">29713452</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>F</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impaired GABA neural circuits are critical for fragile X syndrome</article-title><source>Neural Plasticity</source><volume>2018</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1155/2018/8423420</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germann</surname> <given-names>AL</given-names></name><name><surname>Steinbach</surname> <given-names>JH</given-names></name><name><surname>Akk</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Application of the co-agonist concerted transition model to analysis of GABAA receptor properties</article-title><source>Current Neuropharmacology</source><volume>17</volume><fpage>843</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.2174/1570159X17666181206092418</pub-id><pub-id pub-id-type="pmid">30520374</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname> <given-names>TT</given-names></name><name><surname>Chan</surname> <given-names>CY</given-names></name><name><surname>Czajkowski</surname> <given-names>CM</given-names></name><name><surname>Farb</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Benzodiazepine receptor photoaffinity labeling: correlation of function with binding</article-title><source>European Journal of Pharmacology</source><volume>110</volume><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(85)90209-2</pub-id><pub-id pub-id-type="pmid">2985408</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gielen</surname> <given-names>MC</given-names></name><name><surname>Lumb</surname> <given-names>MJ</given-names></name><name><surname>Smart</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Benzodiazepines modulate GABAA receptors by regulating the preactivation step after GABA binding</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>5707</fpage><lpage>5715</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5663-11.2012</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschen-Ohm</surname> <given-names>MP</given-names></name><name><surname>Wagner</surname> <given-names>DA</given-names></name><name><surname>Petrou</surname> <given-names>S</given-names></name><name><surname>Jones</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An epilepsy-related region in the GABA(A) receptor mediates long-distance effects on GABA and benzodiazepine binding sites</article-title><source>Molecular Pharmacology</source><volume>77</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1124/mol.109.058289</pub-id><pub-id pub-id-type="pmid">19846749</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschen-Ohm</surname> <given-names>MP</given-names></name><name><surname>Haroldson</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>MV</given-names></name><name><surname>Pearce</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A nonequilibrium binary elements-based kinetic model for benzodiazepine regulation of GABAA receptors</article-title><source>Journal of General Physiology</source><volume>144</volume><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1085/jgp.201411183</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>S</given-names></name><name><surname>Chakraborty</surname> <given-names>S</given-names></name><name><surname>Vij</surname> <given-names>R</given-names></name><name><surname>Auerbach</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A mechanism for acetylcholine receptor gating based on structure, coupling, phi, and flip</article-title><source>Journal of General Physiology</source><volume>149</volume><fpage>85</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1085/jgp.201611673</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hales</surname> <given-names>TG</given-names></name><name><surname>Deeb</surname> <given-names>TZ</given-names></name><name><surname>Tang</surname> <given-names>H</given-names></name><name><surname>Bollan</surname> <given-names>KA</given-names></name><name><surname>King</surname> <given-names>DP</given-names></name><name><surname>Johnson</surname> <given-names>SJ</given-names></name><name><surname>Connolly</surname> <given-names>CN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An asymmetric contribution to γ-Aminobutyric type A receptor function of a conserved lysine within TM2–3 of α1, β2, and γ2 subunits</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>17034</fpage><lpage>17043</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603599200</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname> <given-names>SM</given-names></name><name><surname>Czajkowski</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structural mechanisms underlying benzodiazepine modulation of the GABAA receptor</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>3490</fpage><lpage>3499</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5727-07.2008</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname> <given-names>SM</given-names></name><name><surname>Czajkowski</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Disulphide trapping of the GABAA receptor reveals the importance of the coupling interface in the action of benzodiazepines</article-title><source>British Journal of Pharmacology</source><volume>162</volume><fpage>673</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01073.x</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname> <given-names>CC</given-names></name><name><surname>Macdonald</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A structural look at GABA<sub>A</sub> receptor mutations linked to epilepsy syndromes</article-title><source>Brain Research</source><volume>1714</volume><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2019.03.004</pub-id><pub-id pub-id-type="pmid">30851244</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname> <given-names>HK</given-names></name><name><surname>Im</surname> <given-names>WB</given-names></name><name><surname>Carter</surname> <given-names>DB</given-names></name><name><surname>McKinley</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Interaction of β-carboline inverse agonists for the benzodiazepine site with another site on GABAA receptors</article-title><source>British Journal of Pharmacology</source><volume>114</volume><fpage>1040</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1995.tb13310.x</pub-id><pub-id pub-id-type="pmid">7780638</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jackson</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="1992">1992</year><source>Thermodynamics of Membrane Receptors and Channels</source><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>CM</given-names></name><name><surname>Paulozzi</surname> <given-names>LJ</given-names></name><name><surname>Mack</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United states</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>63</volume><fpage>881</fpage><lpage>885</lpage></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>CM</given-names></name><name><surname>McAninch</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines</article-title><source>American Journal of Preventive Medicine</source><volume>49</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2015.03.040</pub-id><pub-id pub-id-type="pmid">26143953</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kash</surname> <given-names>TL</given-names></name><name><surname>Jenkins</surname> <given-names>A</given-names></name><name><surname>Kelley</surname> <given-names>JC</given-names></name><name><surname>Trudell</surname> <given-names>JR</given-names></name><name><surname>Harrison</surname> <given-names>NL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Coupling of agonist binding to channel gating in the GABA<sub>A</sub> receptor</article-title><source>Nature</source><volume>421</volume><fpage>272</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/nature01280</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keramidas</surname> <given-names>A</given-names></name><name><surname>Harrison</surname> <given-names>NL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The activation mechanism of α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> and α<sub>3</sub>β<sub>3</sub>γ<sub>2S</sub> GABA<sub>A</sub> receptors</article-title><source>Journal of General Physiology</source><volume>135</volume><fpage>59</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1085/jgp.200910317</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>JJ</given-names></name><name><surname>Gharpure</surname> <given-names>A</given-names></name><name><surname>Teng</surname> <given-names>J</given-names></name><name><surname>Zhuang</surname> <given-names>Y</given-names></name><name><surname>Howard</surname> <given-names>RJ</given-names></name><name><surname>Zhu</surname> <given-names>S</given-names></name><name><surname>Noviello</surname> <given-names>CM</given-names></name><name><surname>Walsh</surname> <given-names>RM</given-names></name><name><surname>Lindahl</surname> <given-names>E</given-names></name><name><surname>Hibbs</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Shared structural mechanisms of general anaesthetics and benzodiazepines</article-title><source>Nature</source><volume>585</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2654-5</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucken</surname> <given-names>AM</given-names></name><name><surname>Wagner</surname> <given-names>DA</given-names></name><name><surname>Ward</surname> <given-names>PR</given-names></name><name><surname>Teissére</surname> <given-names>JA</given-names></name><name><surname>Boileau</surname> <given-names>AJ</given-names></name><name><surname>Czajkowski</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification of benzodiazepine binding site residues in the gamma2 subunit of the gamma-aminobutyric acid(A) receptor</article-title><source>Molecular Pharmacology</source><volume>57</volume><fpage>932</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">10779376</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Basak</surname> <given-names>S</given-names></name><name><surname>Rao</surname> <given-names>S</given-names></name><name><surname>Gicheru</surname> <given-names>Y</given-names></name><name><surname>Mayer</surname> <given-names>ML</given-names></name><name><surname>Sansom</surname> <given-names>MSP</given-names></name><name><surname>Chakrapani</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of activation and desensitization of full-length glycine receptor in lipid nanodiscs</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3752</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17364-5</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laverty</surname> <given-names>D</given-names></name><name><surname>Desai</surname> <given-names>R</given-names></name><name><surname>Uchański</surname> <given-names>T</given-names></name><name><surname>Masiulis</surname> <given-names>S</given-names></name><name><surname>Stec</surname> <given-names>WJ</given-names></name><name><surname>Malinauskas</surname> <given-names>T</given-names></name><name><surname>Zivanov</surname> <given-names>J</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Miller</surname> <given-names>KW</given-names></name><name><surname>Aricescu</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryo-EM structure of the human α1β3γ2 GABA<sub>A</sub> receptor in a lipid bilayer</article-title><source>Nature</source><volume>565</volume><fpage>516</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0833-4</pub-id><pub-id pub-id-type="pmid">30602789</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Eaton</surname> <given-names>MM</given-names></name><name><surname>Steinbach</surname> <given-names>JH</given-names></name><name><surname>Akk</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The benzodiazepine diazepam potentiates responses of α1β2γ2L γ-aminobutyric acid type A receptors activated by either γ-aminobutyric acid or allosteric agonists</article-title><source>Anesthesiology</source><volume>118</volume><fpage>1417</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e318289bcd3</pub-id><pub-id pub-id-type="pmid">23407108</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limon</surname> <given-names>A</given-names></name><name><surname>Reyes-Ruiz</surname> <given-names>JM</given-names></name><name><surname>Miledi</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Loss of functional GABA(A) receptors in the alzheimer diseased brain</article-title><source>PNAS</source><volume>109</volume><fpage>10071</fpage><lpage>10076</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204606109</pub-id><pub-id pub-id-type="pmid">22691495</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahdavi</surname> <given-names>M</given-names></name><name><surname>Kheirollahi</surname> <given-names>M</given-names></name><name><surname>Riahi</surname> <given-names>R</given-names></name><name><surname>Khorvash</surname> <given-names>F</given-names></name><name><surname>Khorrami</surname> <given-names>M</given-names></name><name><surname>Mirsafaie</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Meta-Analysis of the association between GABA receptor polymorphisms and autism spectrum disorder (ASD)</article-title><source>Journal of Molecular Neuroscience</source><volume>65</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s12031-018-1073-7</pub-id><pub-id pub-id-type="pmid">29725984</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maksay</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Thermodynamics of gamma-aminobutyric acid type A receptor binding differentiate agonists from antagonists</article-title><source>Molecular Pharmacology</source><volume>46</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/BF00168633</pub-id><pub-id pub-id-type="pmid">8078501</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masiulis</surname> <given-names>S</given-names></name><name><surname>Desai</surname> <given-names>R</given-names></name><name><surname>Uchański</surname> <given-names>T</given-names></name><name><surname>Serna Martin</surname> <given-names>I</given-names></name><name><surname>Laverty</surname> <given-names>D</given-names></name><name><surname>Karia</surname> <given-names>D</given-names></name><name><surname>Malinauskas</surname> <given-names>T</given-names></name><name><surname>Zivanov</surname> <given-names>J</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Kotecha</surname> <given-names>A</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Miller</surname> <given-names>KW</given-names></name><name><surname>Aricescu</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GABA<sub>A</sub> receptor signalling mechanisms revealed by structural pharmacology</article-title><source>Nature</source><volume>565</volume><fpage>454</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0832-5</pub-id><pub-id pub-id-type="pmid">30602790</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKernan</surname> <given-names>RM</given-names></name><name><surname>Farrar</surname> <given-names>S</given-names></name><name><surname>Collins</surname> <given-names>I</given-names></name><name><surname>Emms</surname> <given-names>F</given-names></name><name><surname>Asuni</surname> <given-names>A</given-names></name><name><surname>Quirk</surname> <given-names>K</given-names></name><name><surname>Broughton</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Photoaffinity labeling of the benzodiazepine binding site of alpha1beta3gamma2 gamma-aminobutyric acidA receptors with flunitrazepam identifies a subset of ligands that interact directly with His102 of the alpha subunit and predicts orientation of these within the benzodiazepine pharmacophore</article-title><source>Molecular Pharmacology</source><volume>54</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1124/mol.54.1.33</pub-id><pub-id pub-id-type="pmid">9658187</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellor</surname> <given-names>JR</given-names></name><name><surname>Randall</surname> <given-names>AD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Frequency-dependent actions of benzodiazepines on GABAA receptors in cultured murine cerebellar granule cells</article-title><source>The Journal of Physiology</source><volume>503 ( Pt 2</volume><fpage>353</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.1997.353bh.x</pub-id><pub-id pub-id-type="pmid">9306278</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Möhler</surname> <given-names>H</given-names></name><name><surname>Fritschy</surname> <given-names>JM</given-names></name><name><surname>Rudolph</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A new benzodiazepine pharmacology</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>300</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1124/jpet.300.1.2</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname> <given-names>TK</given-names></name><name><surname>Vij</surname> <given-names>R</given-names></name><name><surname>Bruhova</surname> <given-names>I</given-names></name><name><surname>Shandilya</surname> <given-names>J</given-names></name><name><surname>Auerbach</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Efficiency measures the conversion of agonist binding energy into receptor conformational change</article-title><source>Journal of General Physiology</source><volume>151</volume><fpage>465</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1085/jgp.201812215</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemecz</surname> <given-names>Ákos</given-names></name><name><surname>Prevost</surname> <given-names>MS</given-names></name><name><surname>Menny</surname> <given-names>A</given-names></name><name><surname>Corringer</surname> <given-names>P-J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging Molecular Mechanisms of Signal Transduction in Pentameric Ligand-Gated Ion Channels</article-title><source>Neuron</source><volume>90</volume><fpage>452</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.03.032</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Shea</surname> <given-names>SM</given-names></name><name><surname>Williams</surname> <given-names>CA</given-names></name><name><surname>Jenkins</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inverse effects on gating and modulation caused by a mutation in the M2-M3 linker of the GABA(A) receptor gamma subunit</article-title><source>Molecular Pharmacology</source><volume>76</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1124/mol.109.055111</pub-id><pub-id pub-id-type="pmid">19553237</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Shea</surname> <given-names>SM</given-names></name><name><surname>Harrison</surname> <given-names>NL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Arg-274 and Leu-277 of the γ-Aminobutyric Acid Type A Receptor α2 Subunit Define Agonist Efficacy and Potency</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>22764</fpage><lpage>22768</lpage><pub-id pub-id-type="doi">10.1074/jbc.M001299200</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olfson</surname> <given-names>M</given-names></name><name><surname>King</surname> <given-names>M</given-names></name><name><surname>Schoenbaum</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Benzodiazepine use in the United States</article-title><source>JAMA Psychiatry</source><volume>72</volume><fpage>136</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.1763</pub-id><pub-id pub-id-type="pmid">25517224</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname> <given-names>RW</given-names></name><name><surname>Sieghart</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function</article-title><source>Pharmacological Reviews</source><volume>60</volume><fpage>243</fpage><lpage>260</lpage></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrais</surname> <given-names>D</given-names></name><name><surname>Ropert</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Effect of zolpidem on miniature IPSCs and occupancy of postsynaptic GABAA receptors in central synapses</article-title><source>The Journal of Neuroscience</source><volume>19</volume><fpage>578</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-02-00578.1999</pub-id><pub-id pub-id-type="pmid">9880578</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflanz</surname> <given-names>NC</given-names></name><name><surname>Daszkowski</surname> <given-names>AW</given-names></name><name><surname>Cornelison</surname> <given-names>GL</given-names></name><name><surname>Trudell</surname> <given-names>JR</given-names></name><name><surname>Mihic</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An intersubunit electrostatic interaction in the GABAA receptor facilitates its responses to benzodiazepines</article-title><source>Journal of Biological Chemistry</source><volume>293</volume><fpage>8264</fpage><lpage>8274</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002128</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phulera</surname> <given-names>S</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Claxton</surname> <given-names>DP</given-names></name><name><surname>Yoder</surname> <given-names>N</given-names></name><name><surname>Yoshioka</surname> <given-names>C</given-names></name><name><surname>Gouaux</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2s tri-heteromeric GABA<sub>A</sub> receptor in complex with GABA</article-title><source>eLife</source><volume>7</volume><elocation-id>e39383</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.39383</pub-id><pub-id pub-id-type="pmid">30044221</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pless</surname> <given-names>SA</given-names></name><name><surname>Sivilotti</surname> <given-names>LG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A tale of ligands big and small: an update on how pentameric ligand-gated ion channels interact with agonists and proteins</article-title><source>Current Opinion in Physiology</source><volume>2</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.cophys.2017.12.012</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchett</surname> <given-names>DB</given-names></name><name><surname>Sontheimer</surname> <given-names>H</given-names></name><name><surname>Shivers</surname> <given-names>BD</given-names></name><name><surname>Ymer</surname> <given-names>S</given-names></name><name><surname>Kettenmann</surname> <given-names>H</given-names></name><name><surname>Schofield</surname> <given-names>PR</given-names></name><name><surname>Seeburg</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology</article-title><source>Nature</source><volume>338</volume><fpage>582</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1038/338582a0</pub-id><pub-id pub-id-type="pmid">2538761</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname> <given-names>P</given-names></name><name><surname>Gupta</surname> <given-names>S</given-names></name><name><surname>Jadey</surname> <given-names>S</given-names></name><name><surname>Auerbach</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functional anatomy of an allosteric protein</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2984</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3984</pub-id><pub-id pub-id-type="pmid">24352193</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname> <given-names>P</given-names></name><name><surname>Auerbach</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Unliganded gating of acetylcholine receptor channels</article-title><source>PNAS</source><volume>106</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809272106</pub-id><pub-id pub-id-type="pmid">19114650</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramamoorthi</surname> <given-names>K</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The contribution of GABAergic dysfunction to neurodevelopmental disorders</article-title><source>Trends in Molecular Medicine</source><volume>17</volume><fpage>452</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2011.03.003</pub-id><pub-id pub-id-type="pmid">21514225</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname> <given-names>CJ</given-names></name><name><surname>Twyman</surname> <given-names>RE</given-names></name><name><surname>Macdonald</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Benzodiazepine and beta-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture</article-title><source>The Journal of Physiology</source><volume>475</volume><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1994.sp020050</pub-id><pub-id pub-id-type="pmid">7514665</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudolph</surname> <given-names>U</given-names></name><name><surname>Möhler</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>GABAA receptor subtypes: therapeutic potential in down syndrome, affective disorders, schizophrenia, and autism</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>54</volume><fpage>483</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011613-135947</pub-id><pub-id pub-id-type="pmid">24160694</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rüsch</surname> <given-names>D</given-names></name><name><surname>Forman</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Classic benzodiazepines modulate the Open–Close Equilibrium in α1β2γ2L γ-Aminobutyric Acid Type A Receptors</article-title><source>Anesthesiology</source><volume>102</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1097/00000542-200504000-00014</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheller</surname> <given-names>M</given-names></name><name><surname>Forman</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Coupled and uncoupled gating and desensitization effects by pore domain mutations in GABA(A) receptors</article-title><source>The Journal of Neuroscience</source><volume>22</volume><fpage>8411</fpage><lpage>8421</lpage><pub-id pub-id-type="pmid">12351715</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Benzodiazepine use, misuse, and abuse: a review</article-title><source>Mental Health Clinician</source><volume>6</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.9740/mhc.2016.05.120</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieghart</surname> <given-names>W</given-names></name><name><surname>Sperk</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Subunit composition, distribution and function of GABA(A) receptor subtypes</article-title><source>Current Topics in Medicinal Chemistry</source><volume>2</volume><fpage>795</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.2174/1568026023393507</pub-id><pub-id pub-id-type="pmid">12171572</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigel</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mapping of the benzodiazepine recognition site on GABA(A) receptors</article-title><source>Current Topics in Medicinal Chemistry</source><volume>2</volume><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.2174/1568026023393444</pub-id><pub-id pub-id-type="pmid">12171574</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigel</surname> <given-names>E</given-names></name><name><surname>Ernst</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The benzodiazepine binding sites of GABA<sub>A</sub> Receptors</article-title><source>Trends in Pharmacological Sciences</source><volume>39</volume><fpage>659</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.03.006</pub-id><pub-id pub-id-type="pmid">29716746</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigel</surname> <given-names>E</given-names></name><name><surname>Lüscher</surname> <given-names>BP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A closer look at the high affinity benzodiazepine binding site on GABAA receptors</article-title><source>Current Topics in Medicinal Chemistry</source><volume>11</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.2174/156802611794863562</pub-id><pub-id pub-id-type="pmid">21189125</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname> <given-names>TG</given-names></name><name><surname>Stephenson</surname> <given-names>FA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A half century of γ-aminobutyric acid</article-title><source>Brain and Neuroscience Advances</source><volume>3</volume><elocation-id>239821281985824</elocation-id><pub-id pub-id-type="doi">10.1177/2398212819858249</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solís-Añez</surname> <given-names>E</given-names></name><name><surname>Delgado-Luengo</surname> <given-names>W</given-names></name><name><surname>Hernández</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Autism, chromosome 15 and the GABAergic dysfunction hypothesis</article-title><source>Investigacion Clinica</source><volume>48</volume><fpage>529</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">18271397</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbach</surname> <given-names>JH</given-names></name><name><surname>Akk</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Applying the Monod-Wyman-Changeux allosteric activation model to Pseudo-Steady-State responses from GAB<sub>A<sub>A</sub></sub>Receptors</article-title><source>Molecular Pharmacology</source><volume>95</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1124/mol.118.113787</pub-id><pub-id pub-id-type="pmid">30333132</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasneem</surname> <given-names>A</given-names></name><name><surname>Iyer</surname> <given-names>LM</given-names></name><name><surname>Jakobsson</surname> <given-names>E</given-names></name><name><surname>Aravind</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Identification of the prokaryotic ligand-gated ion channels and their implications for the mechanisms and origins of animal Cys-loop ion channels</article-title><source>Genome Biology</source><volume>6</volume><elocation-id>R4</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2004-6-1-r4</pub-id><pub-id pub-id-type="pmid">15642096</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatachalan</surname> <given-names>SP</given-names></name><name><surname>Czajkowski</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural link between γ-Aminobutyric acid type A (GABAA) Receptor agonist binding site and inner β-Sheet governs channel activation and allosteric drug modulation</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>6714</fpage><lpage>6724</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.316836</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicini</surname> <given-names>S</given-names></name><name><surname>Mienville</surname> <given-names>JM</given-names></name><name><surname>Costa</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Actions of benzodiazepine and beta-carboline derivatives on gamma-aminobutyric acid-activated Cl- channels recorded from membrane patches of neonatal rat cortical neurons in culture</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>243</volume><fpage>1195</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">2447266</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vien</surname> <given-names>TN</given-names></name><name><surname>Modgil</surname> <given-names>A</given-names></name><name><surname>Abramian</surname> <given-names>AM</given-names></name><name><surname>Jurd</surname> <given-names>R</given-names></name><name><surname>Walker</surname> <given-names>J</given-names></name><name><surname>Brandon</surname> <given-names>NJ</given-names></name><name><surname>Terunuma</surname> <given-names>M</given-names></name><name><surname>Rudolph</surname> <given-names>U</given-names></name><name><surname>Maguire</surname> <given-names>J</given-names></name><name><surname>Davies</surname> <given-names>PA</given-names></name><name><surname>Moss</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Compromising the phosphodependent regulation of the GABAAR β3 subunit reproduces the core phenotypes of autism spectrum disorders</article-title><source>PNAS</source><volume>112</volume><fpage>14805</fpage><lpage>14810</lpage><pub-id pub-id-type="doi">10.1073/pnas.1514657112</pub-id><pub-id pub-id-type="pmid">26627235</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>DA</given-names></name><name><surname>Czajkowski</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structure and dynamics of the GABA binding pocket: a narrowing cleft that constricts during activation</article-title><source>The Journal of Neuroscience</source><volume>21</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-01-00067.2001</pub-id><pub-id pub-id-type="pmid">11150321</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname> <given-names>RJ</given-names></name><name><surname>Hadley</surname> <given-names>SH</given-names></name><name><surname>Morris</surname> <given-names>KD</given-names></name><name><surname>Amin</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms</article-title><source>Nature Neuroscience</source><volume>3</volume><fpage>1274</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1038/81800</pub-id><pub-id pub-id-type="pmid">11100148</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wyman</surname> <given-names>J</given-names></name><name><surname>Gill</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1990">1990</year><source>Binding and Linkage: Functional Chemistry of Biological Macromolecules</source><publisher-name>University Science Books</publisher-name><pub-id pub-id-type="doi">10.1016/0014-5793(91)81192-B</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>S</given-names></name><name><surname>Noviello</surname> <given-names>CM</given-names></name><name><surname>Teng</surname> <given-names>J</given-names></name><name><surname>Walsh</surname> <given-names>RM</given-names></name><name><surname>Kim</surname> <given-names>JJ</given-names></name><name><surname>Hibbs</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of a human synaptic GABAA receptor</article-title><source>Nature</source><volume>559</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0255-3</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64400.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Islas</surname><given-names>Leon D</given-names></name><role>Reviewing Editor</role><aff><institution>Universidad Nacional Autónoma de México</institution><country>Mexico</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Islas</surname><given-names>Leon D</given-names></name><role>Reviewer</role><aff><institution>Universidad Nacional Autónoma de México</institution><country>Mexico</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Hibbs</surname><given-names>Ryan E</given-names></name><role>Reviewer</role><aff><institution>University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>In this work, the authors make use of a gain of function mutant in the GABA-A receptor to study the mechanism of action of benzodiazepines (BDZ), not actual activators, but allosteric modulators of the function of the receptor. This work is important because the action of allosteric modulators is often difficult to study in the absence of a full ligand, which makes studying allosteric coupling extremely difficult. Since BDZ have important clinical applications, this work should further our understanding of the mechanisms of these important drugs. The work identifies a critical amino acid residue which regulates the actions of BDZs. This is an important finding, which opens new avenues to understand the molecular biophysics of GABA receptors.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A critical residue in the α<sub>1</sub>M2-M3 linker regulating GABA<sub>A</sub> receptor pore gating by diazepam&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Leon D Islas as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Kenton Swartz as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Ryan E Hibbs (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>Nors et al. have investigated the effects of mutations to the M2-M3 linker in the α1 subunit on α1β2γ2 GABA-A receptor gating by GABA and diazepam. For simplicity, the experiments were conducted on the L9'T background that enhances unliganded gating and enables measurement of current in the presence of diazepam alone. Replacement of each individual residue (6 in total) by alanine indicated that the V279A enhances gating efficacy by diazepam while other substitutions were largely without effect. Comparison of alanine, tryptophan and aspartate substitutions at V279 suggested that side chain volume at this position is critical to gating by diazepam. Overall, the experiments are expertly conducted and support major conclusions. The manuscript is very well organized and written, but it raises questions that could be easily addressed in the confounds of this study.</p><p>A major conclusion of the present manuscript suggests that another class of ligands binding in the intersubunit interface in the extracellular domain employs the M2-M3 linker in energy transduction. This finding is interesting but not unexpected. Furthermore, the finding is not particularly well studied. However, the study includes important advances that will be of interest to the LGIC community, but could be improved through consideration of additional experiments, and more careful pruning of hypotheses presented in the Discussion after looking at GlyR (or other) structures.</p><p>Essential revisions:</p><p>1) Why were not all M2-M3 linker residues mutated? Specifically, the 280 and 282 positions, but beyond these the M2-M3 linker extends as far as F288. Also, please provide a sequence alignment for the M2-M3 linker region for α1, β2, and γ2 subunits.</p><p>2) The authors should test the effect of V279A on BZD negative modulators. Is inverse agonism similarly affected?</p><p>3) Testing a few key positions in the γ subunit M2-M3 linker would make the story stronger. Many questions are left unanswered – does the γ subunit M2-M3 linker affect gating by diazepam? Does it affect gating by GABA? In any case, the effects of the Ala substitutions in the α subunit should be formally analyzed for gating by GABA. These data are already available, just no analysis was done.</p><p>4) If V279 is so important for gating and energy transduction, its interacting counterpart should be defined. Molecular modeling should help determine the nearby residues in ECD, then mutate V279 and the counterparts individually and in combination, followed by double mutant cycle analysis.</p><p>5) A main assumption in this work is that all mutants will have the same or very similar open probability to the background channels and to WT channels gated by GABA. This assumption might seem reasonable but should be checked experimentally through single channel recording, especially for the 279A channels.</p><p>6) It is important to fully justify the two corrections applied to the data that are shown in Figure 2—figure supplement 1. Do all channels show a constant reduction of current size during the experiment? If not, is there evidence of gating mode-shifting during the recording period? What is the reason that in the second linear scaling, the size of the last current is chosen as the normalizing factor?</p><p>7) Subsection “α<sub>1</sub>L9’T and α<sub>1</sub>V279A have independent and additive effects on the pore gating equilibrium”: the model assumes independent GABA and DZP binding. Is this reasonable? Their binding is cooperative, isn't it, with DZP binding shifting the affinity for GABA a few fold to the left (higher affinity)?</p><p>8) Setting up the first section in the Results with a clear rationale for looking at unliganded gating would improve readability.</p><p>9) Some direct experimental comparison of WT and L9'T, including extent of ptx-sensitive leak, would be helpful.</p><p>10) Discussion: it may be worthwhile to look at structures of the related glycine receptor, which have been obtained in resting, open and closed conformational states- is the V279 “obstruction” doing something interesting that you can make more broadly relevant, as well as place it in the context of experimental structures? Do the mutagenesis results (Trp, Asp mutants) make sense in the context of state changes in these comparable structures? Or are the GlyR structures not useful for refining hypotheses on this topic?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64400.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Why were not all M2-M3 linker residues mutated? Specifically, the 280 and 282 positions, but beyond these the M2-M3 linker extends as far as F288. Also, please provide a sequence alignment for the M2-M3 linker region for α1, β2, and γ2 subunits.</p></disp-quote><p>Positions 280 and 282 are both alanine natively in α1, and thus were not mutated for the alanine scan. Regarding the extension of the M2-M3 linker as far as F288, we simply restricted our analysis to the flexible loop region between the helical regions associated with M2 and M3 as resolved in recent structures. We have amended the text to make these points clear. We have also added Figure 1—figure supplement 1 which shows a sequence alignment of the M2-M3 linker regions as requested.</p><disp-quote content-type="editor-comment"><p>2) The authors should test the effect of V279A on BZD negative modulators. Is inverse agonism similarly affected?</p></disp-quote><p>We have added a new supplementary figure, Figure 8—figure supplement 1, showing the effects of the BZD negative modulator FG-7142 on WT and V279A receptors. We have also added a paragraph in the Results describing these data.</p><disp-quote content-type="editor-comment"><p>3) Testing a few key positions in the γ subunit M2-M3 linker would make the story stronger. Many questions are left unanswered – does the γ subunit M2-M3 linker affect gating by diazepam? Does it affect gating by GABA? In any case, the effects of the Ala substitutions in the α subunit should be formally analyzed for gating by GABA. These data are already available, just no analysis was done.</p></disp-quote><p>We agree with the reviewers that looking at the effect of M2-M3 linker mutations in other subunits such as g would be interesting. However, to do this well would require at least another entire scan equivalent to that currently reported. Even with a key residue such as V279, there are multiple combinations with a, b and g subunits that should be examined. We feel that this would be more appropriate as its own follow-up investigation.</p><p>Regarding effects of the mutations on gating by GABA, we have appended an additional Results section and new supplementary figure, Figure 9—figure supplement 1 describing application of the model in Figure 9A to GABA P<sub>o</sub> curves for all alanine mutations.</p><disp-quote content-type="editor-comment"><p>4) If V279 is so important for gating and energy transduction, its interacting counterpart should be defined. Molecular modeling should help determine the nearby residues in ECD, then mutate V279 and the counterparts individually and in combination, followed by double mutant cycle analysis.</p></disp-quote><p>We appreciate the desire to identify specific interaction counterparts. However, double mutant cycle analysis using current responses can lead to inaccurate estimates of the interaction energies if the closed and open reference states are not the same for all mutants (see PMC4210424), which is a distinct possibility in this case. Furthermore, the energies we are talking about here are fairly small, with V279A’s effect on DZ gating being only -0.4 kcal/mol. The clear effect on channel current of such small energetic perturbations is made possible by the small energy difference between closed and open states in the L9'T mutant. Resolving the details of weak interactions on this scale that may also involve interactions with backbone is likely to be nontrivial and we feel would constitute a study in its own right.</p><disp-quote content-type="editor-comment"><p>5) A main assumption in this work is that all mutants will have the same or very similar open probability to the background channels and to WT channels gated by GABA. This assumption might seem reasonable but should be checked experimentally through single channel recording, especially for the 279A channels.</p></disp-quote><p>We agree with the reviewers. We have added a new supplementary figure, Figure 7—figure supplement 1 that shows data for a single L9'T/V279A channel in saturating GABA. Po during prolonged bursting is ~0.93, consistent with the assumed high open probability of constructs in the L9'T background. We have also added a Materials and methods section for these recordings. Due to the experimental challenge in obtaining these data, we restricted this verification to V279A only.</p><disp-quote content-type="editor-comment"><p>6) It is important to fully justify the two corrections applied to the data that are shown in Figure 2—figure supplement 1. Do all channels show a constant reduction of current size during the experiment? If not, is there evidence of gating mode-shifting during the recording period? What is the reason that in the second linear scaling, the size of the last current is chosen as the normalizing factor?</p></disp-quote><p>The amount of current rundown observed was variable across oocytes, with no clear relation to specific constructs. There was no clear evidence of a gating mode shift that we could discern from our recordings. Also, responses for the same construct were similar after correction for oocytes with either clearly obvious or nearly non-existent rundown. We have added a statement to this effect in the Materials and methods. For the second linear scaling, the choice of the last current as the normalizing factor is arbitrary as all currents were normalized to their PTX response for comparison across oocytes.</p><disp-quote content-type="editor-comment"><p>7) Subsection “α<sub>1</sub>L9’T and α<sub>1</sub>V279A have independent and additive effects on the pore gating equilibrium”: the model assumes independent GABA and DZP binding. Is this reasonable? Their binding is cooperative, isn't it, with DZP binding shifting the affinity for GABA a few fold to the left (higher affinity)?</p></disp-quote><p>For the MWC model in Figure 9A, cooperativity stems from the different affinities in closed versus open states. Thus, even though binding steps are independent, DZ binding will alter the equilibrium between closed and open states and thereby alter overall GABA binding, and vice versa. Nonetheless, as we acknowledge in the text, this model does not perfectly describe observations for WT channels with DZ and GABA in combination, and thus a more complicated mechanism may be required. Regardless, the simple model used here does do a reasonable job of describing our observations in the L9'T background.</p><disp-quote content-type="editor-comment"><p>8) Setting up the first section in the Results with a clear rationale for looking at unliganded gating would improve readability.</p></disp-quote><p>We agree that this will be helpful for readers and have added some explanation to the beginning of the first Results section.</p><disp-quote content-type="editor-comment"><p>9) Some direct experimental comparison of WT and L9'T, including extent of ptx-sensitive leak, would be helpful.</p></disp-quote><p>We have added a new supplementary figure, Figure 2—figure supplement 3 which illustrates WT responses to GABA, PTX and DZ.</p><disp-quote content-type="editor-comment"><p>10) Discussion: it may be worthwhile to look at structures of the related glycine receptor, which have been obtained in resting, open and closed conformational states- is the V279 “obstruction” doing something interesting that you can make more broadly relevant, as well as place it in the context of experimental structures? Do the mutagenesis results (Trp, Asp mutants) make sense in the context of state changes in these comparable structures? Or are the GlyR structures not useful for refining hypotheses on this topic?</p></disp-quote><p>The GlyR structures are certainly of value for refining hypotheses regarding pLGICs. As such, we now discuss them briefly in the Discussion. The GlyR structures in general paint a very similar picture to that from GABA<sub>A</sub>R and AChR structures. Thus, the role of position 279 is likely conserved in other pLGICs, and we have added a sentence aimed at broadening the relevance for this site (Discussion). In our opinion, the structures do not however make the exact mechanism for each of the mutations completely clear. Given the relatively small energetic effects that we observe and the resolution of these models, it is likely the case that additional experiments or MD simulations will be needed to resolve these details.</p></body></sub-article></article>